Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.

[1]  B. Cormand,et al.  Levodopa‐induced dyskinesias in tyrosine hydroxylase deficiency , 2013, Movement disorders : official journal of the Movement Disorder Society.

[2]  R. Arai,et al.  Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenousl-DOPA in the rat, with reference to the involvement of aromaticl-amino acid decar☐ylase , 1994, Brain Research.

[3]  W Zieglgänsberger,et al.  [3h]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain , 2003, Neuroscience.

[4]  J. Dostrovsky,et al.  Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. , 2001, Journal of neurophysiology.

[5]  C. Marsden,et al.  Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease , 1995, Neuroscience.

[6]  F. Mastaglia,et al.  Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[7]  M. Tyers,et al.  A new family of regulators of G-protein-coupled receptors? , 1996, Current Biology.

[8]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[9]  C. Lüscher,et al.  D1R/GluN1 complexes in the striatum integrate dopamine and glutamate signalling to control synaptic plasticity and cocaine-induced responses , 2014, Molecular Psychiatry.

[10]  W. Olson,et al.  Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. , 1997, The American journal of medicine.

[11]  U. Ungerstedt Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. , 1971, Acta physiologica Scandinavica. Supplementum.

[12]  E. Bézard,et al.  Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. , 2004, European journal of pharmacology.

[13]  D. Centonze,et al.  d-Aspartate Prevents Corticostriatal Long-Term Depression and Attenuates Schizophrenia-Like Symptoms Induced by Amphetamine and MK-801 , 2008, The Journal of Neuroscience.

[14]  R. Todd,et al.  Dynamic Changes in Striatal Dopamine D2 and D3 Receptor Protein and mRNA in Response to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Denervation in Baboons , 1996, The Journal of Neuroscience.

[15]  R. Huganir,et al.  Control of GluR1 AMPA Receptor Function by cAMP-Dependent Protein Kinase , 2000, The Journal of Neuroscience.

[16]  D. Riche,et al.  A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon , 1990, Experimental Neurology.

[17]  B. Bloch,et al.  D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAS in distinct neuronal populations of the dorsal and ventral striatum , 1995, The Journal of comparative neurology.

[18]  M. Barrot,et al.  ΔFosB: A sustained molecular switch for addiction , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Beal,et al.  Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.

[20]  R. Maj,et al.  Safinamide , 2006, Neurology.

[21]  J. Henley,et al.  Lateral Diffusion Drives Constitutive Exchange of AMPA Receptors at Dendritic Spines and Is Regulated by Spine Morphology , 2006, The Journal of Neuroscience.

[22]  [L-dopa in Parkinson's syndrome]. , 1971 .

[23]  Theodore G. Wensel,et al.  RGS Expression Rate-Limits Recovery of Rod Photoresponses , 2006, Neuron.

[24]  J. Brotchie,et al.  The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. , 2010, Progress in brain research.

[25]  H. Miwa,et al.  Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats , 2011, Pharmacology Biochemistry and Behavior.

[26]  K. Dalby,et al.  Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation , 2008, Journal of Pharmacology and Experimental Therapeutics.

[27]  T. Chase,et al.  NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats , 2004, Neuropharmacology.

[28]  M. Stacy,et al.  A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease , 2008, Neurology.

[29]  Paul Greengard,et al.  Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia , 2003, Nature Neuroscience.

[30]  A. Holman Impulse Control Disorder Behaviors Associated with Pramipexole Used to Treat Fibromyalgia , 2009, Journal of Gambling Studies.

[31]  S. L. Nicholson,et al.  Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[32]  Andrew J Lees,et al.  Pathological gambling in Parkinson's disease—a review of the literature , 2011, Movement disorders : official journal of the Movement Disorder Society.

[33]  J. Brotchie,et al.  Serotonin and Parkinson's disease: On movement, mood, and madness , 2009, Movement disorders : official journal of the Movement Disorder Society.

[34]  Qin Li,et al.  Synaptic recruitment of AMPA glutamate receptor subunits in levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate , 2010, Synapse.

[35]  M. Garret,et al.  Distinct Cellular and Subcellular Distributions of G Protein-Coupled Receptor Kinase and Arrestin Isoforms in the Striatum , 2012, PloS one.

[36]  E. Bézard,et al.  Endogenous morphine-like compound immunoreactivity increases in parkinsonism. , 2011, Brain : a journal of neurology.

[37]  P. Petersson,et al.  Levodopa-Induced Dyskinesia Is Strongly Associated with Resonant Cortical Oscillations , 2012, The Journal of Neuroscience.

[38]  M. Nirenberg Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care , 2013, Drugs & Aging.

[39]  E. Bézard,et al.  Levodopa–induced dyskinesias in the absence of nigrostriatal degeneration , 2013, Movement disorders : official journal of the Movement Disorder Society.

[40]  Y. Kawamoto,et al.  RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy , 2011, Dermatology research and practice.

[41]  A. Lees Levodopa Substitution: The Gold Standard , 1994 .

[42]  Talia N. Lerner,et al.  RGS4 Is Required for Dopaminergic Control of Striatal LTD and Susceptibility to Parkinsonian Motor Deficits , 2012, Neuron.

[43]  P. Blanchet,et al.  Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  Adam T. Brewer,et al.  Effects of pramipexole on impulsive choice in male wistar rats. , 2010, Experimental and clinical psychopharmacology.

[45]  C. Sampaio,et al.  Evidence-based medicine (EBM) applied to Parkinson's disease treatment. , 2002, Parkinsonism & related disorders.

[46]  L. Grégoire,et al.  Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys. , 2000, European journal of pharmacology.

[47]  C. Aoki,et al.  Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. , 1992, The Journal of biological chemistry.

[48]  P. Pollak,et al.  Multifocal enhancing cortical lesions in a patient with Churg-Strauss syndrome , 2008, Neurology.

[49]  Y. Agid,et al.  Levodopa‐induced dyskinesias in Parkinson's disease: Is sensitization reversible? , 2000 .

[50]  A. Lees,et al.  Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. , 2004, Drug and alcohol dependence.

[51]  Marina R. Picciotto,et al.  It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood , 2008, Progress in Neurobiology.

[52]  F. Verhey,et al.  Serotonergic mechanisms in Parkinson’s disease: opposing results from preclinical and clinical data , 2005, Journal of Neural Transmission.

[53]  D. Riche,et al.  A primate model of Huntington's disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-putamen , 2004, Experimental Brain Research.

[54]  R. Challiss,et al.  Imaging of Muscarinic Acetylcholine Receptor Signaling in Hippocampal Neurons: Evidence for Phosphorylation-Dependent and -Independent Regulation by G-Protein-Coupled Receptor Kinases , 2004, The Journal of Neuroscience.

[55]  E. Birket-Smith,et al.  ABNORMAL INVOLUNTARY MOVEMENTS INDUCED BY ANTICHOLINERGIC THERAPY , 1974, Acta neurologica Scandinavica.

[56]  B. Averbeck,et al.  Novelty seeking behaviour in Parkinson's disease , 2011, Neuropsychologia.

[57]  A. Benabid,et al.  Effects of magnetic resonance imaging in patients with implanted deep brain stimulation systems. , 2010, Journal of neurosurgery.

[58]  Yoshiaki Washio,et al.  Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery. , 2009, Current opinion in drug discovery & development.

[59]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[60]  N. Pavón,et al.  ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice , 2006, Biological Psychiatry.

[61]  P. Seeman,et al.  Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.

[62]  A. Björklund,et al.  Intrastriatal implants of mesencephalic cell suspensions in weaver mutant mice: ultrastructural relationships of dopaminergic dendrites and axons issued from the graft , 2004, Experimental Brain Research.

[63]  J. Brotchie,et al.  The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[64]  A. Benabid,et al.  Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex , 1999, Journal of neurology, neurosurgery, and psychiatry.

[65]  L. Tremblay,et al.  Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson's disease. , 2003, Brain : a journal of neurology.

[66]  L. Grégoire,et al.  Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. , 2013, Parkinsonism & related disorders.

[67]  S. Snyder,et al.  Cloning and expression of an adenylyl cyclase localized to the corpus striatum , 1993, Nature.

[68]  Erwan Bezard,et al.  Modeling Parkinson's disease in primates: The MPTP model. , 2012, Cold Spring Harbor perspectives in medicine.

[69]  J. McGinty,et al.  Regulator of G-Protein Signaling 4 Interacts with Metabotropic Glutamate Receptor Subtype 5 in Rat Striatum: Relevance to Amphetamine Behavioral Sensitization , 2007, Journal of Pharmacology and Experimental Therapeutics.

[70]  J. Baraban,et al.  The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience , 1999, Trends in Neurosciences.

[71]  U. Ungerstedt,et al.  Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. , 1971, Acta physiologica Scandinavica. Supplementum.

[72]  M. Morelli,et al.  Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6‐hydroxydopamine‐lesioned rats , 2001, Synapse.

[73]  R. Roth,et al.  Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. , 1987, Life sciences.

[74]  C. Gerfen,et al.  Differences between Dorsal and Ventral Striatum in Drd1a Dopamine Receptor Coupling of Dopamine- and cAMP-Regulated Phosphoprotein-32 to Activation of Extracellular Signal-Regulated Kinase , 2008, The Journal of Neuroscience.

[75]  Nicola Simola,et al.  The 6-Hydroxydopamine model of parkinson’s disease , 2007, Neurotoxicity Research.

[76]  G. Fisone,et al.  Dopamine Signaling Leads to Loss of Polycomb Repression and Aberrant Gene Activation in Experimental Parkinsonism , 2014, PLoS genetics.

[77]  P. Calabresi,et al.  Direct and indirect pathways of basal ganglia: a critical reappraisal , 2014, Nature Neuroscience.

[78]  P. Gubellini,et al.  Chronic high‐frequency stimulation of the subthalamic nucleus and L‐DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission , 2006, The European journal of neuroscience.

[79]  W. Ko,et al.  Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease , 2015, Neuroscience.

[80]  J. Langston,et al.  Enhanced striatal opioid receptor-mediated G-protein activation in l-dopa-treated dyskinetic monkeys , 2005, Neuroscience.

[81]  S. Salvadori,et al.  UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. , 2006, CNS drug reviews.

[82]  Daniel B. McClatchy,et al.  Functional specialization of β-arrestin interactions revealed by proteomic analysis , 2007, Proceedings of the National Academy of Sciences.

[83]  J. Langston,et al.  Levodopa induces dyskinesias in normal squirrel monkeys , 2001, Annals of neurology.

[84]  Susan H. Fox,et al.  l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease , 2012, Neuropharmacology.

[85]  MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons , 2010, Neuroscience.

[86]  Robert J. Witte,et al.  Magnetic Resonance Imaging and Deep Brain Stimulation , 2002, Neurosurgery.

[87]  E. Bézard,et al.  Double-dissociation of the catecholaminergic modulation of synaptic transmission in the oval bed nucleus of the stria terminalis. , 2011, Journal of neurophysiology.

[88]  A. Björklund,et al.  l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function , 2002, Neurobiology of Disease.

[89]  P. Greengard The neurobiology of slow synaptic transmission. , 2001, Science.

[90]  M. Beal,et al.  Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase , 1999, Brain Research.

[91]  Hartwig R. Siebner,et al.  Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans , 2015, Brain : a journal of neurology.

[92]  J. Benovic,et al.  Altered expression and subcellular distribution of GRK subtypes in the dopamine‐depleted rat basal ganglia is not normalized by l‐DOPA treatment , 2008, Journal of neurochemistry.

[93]  M. Quik,et al.  α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease , 2011, Pharmacological Reviews.

[94]  J. Deniau,et al.  Disinhibition as a basic process in the expression of striatal functions , 1990, Trends in Neurosciences.

[95]  D. Brooks,et al.  An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers , 2010, Clinical neuropharmacology.

[96]  M. Baba,et al.  Upregulation of striatal adenosine A2A receptor mRNA in 6‐hydroxydopamine‐lesioned rats intermittently treated with L‐DOPA , 2004, Synapse.

[97]  H. Reichmann,et al.  Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial , 2010, Journal of Neural Transmission.

[98]  O. Hornykiewicz,et al.  Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.

[99]  Pardeep Singh,et al.  Striatal Cholinergic Cell Ablation Attenuates l-DOPA Induced Dyskinesia in Parkinsonian Mice , 2014, The Journal of Neuroscience.

[100]  F. Gasparini,et al.  Metabotropic Glutamate Receptors for Parkinson's Disease Therapy , 2013, Parkinson's disease.

[101]  D. Erlij,et al.  l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata , 2011, Neurobiology of Disease.

[102]  Yen F. Tai,et al.  Compulsive drug use linked to sensitized ventral striatal dopamine transmission , 2006, Annals of neurology.

[103]  L. Grégoire,et al.  Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. , 2004, Parkinsonism & related disorders.

[104]  Daniel Choquet,et al.  New Concepts in Synaptic Biology Derived from Single-Molecule Imaging , 2008, Neuron.

[105]  J. Benovic,et al.  β-Arrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor , 1996, Nature.

[106]  A. Mushegian,et al.  The Origin and Evolution of G Protein-Coupled Receptor Kinases , 2012, PloS one.

[107]  A. Aristieta,et al.  Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in l-DOPA-treated rats , 2014, Neuropharmacology.

[108]  A. Lees,et al.  Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD , 2008, Neurology.

[109]  J. C. Stoof,et al.  Priming with L-DOPA differently affects dynorphin and substance P mRNA levels in the striatum of 6-hydroxydopamine-lesioned rats after challenge with dopamine D1-receptor agonist. , 1998, Brain research. Molecular brain research.

[110]  G. Breese,et al.  6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. , 1987, The Journal of pharmacology and experimental therapeutics.

[111]  D. Segal Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) , 2010 .

[112]  E. Wolf,et al.  Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[113]  E. Bézard,et al.  Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss , 2013, Annals of neurology.

[114]  L. Brandenburg,et al.  Role of receptor internalization in the agonist‐induced desensitization of cannabinoid type 1 receptors , 2008, Journal of neurochemistry.

[115]  R. Bakay,et al.  Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.

[116]  G. Di Chiara,et al.  Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning. , 1987, European journal of pharmacology.

[117]  J. Drouin,et al.  Striatal neuroadaptation and rescue of locomotor deficit by l‐dopa in aphakia mice, a model of Parkinson's disease , 2006, Journal of neurochemistry.

[118]  F. Monsma,et al.  Structure-Activity Relationship Studies on the Novel Neuropeptide Orphanin FQ* , 1996, The Journal of Biological Chemistry.

[119]  Hartwig R. Siebner,et al.  The acute brain response to levodopa heralds dyskinesias in Parkinson disease , 2014, Annals of neurology.

[120]  A. Strafella,et al.  Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease? , 2009, Neuropsychopharmacology.

[121]  M. Morari,et al.  Amantadine attenuates levodopa‐induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels , 2011, Journal of neurochemistry.

[122]  C. Marsden,et al.  COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA , 1982, The Lancet.

[123]  M. Cenci Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia , 2007, Trends in Neurosciences.

[124]  C. Goetz,et al.  Hallucinations in Parkinson disease in the prelevodopa era , 2006, Neurology.

[125]  Jian Wang,et al.  Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD , 2001, Neurology.

[126]  David R Williams,et al.  Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study , 2005, The Lancet Neurology.

[127]  L. Grégoire,et al.  Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys , 2013, Neuropharmacology.

[128]  G. Bernardi,et al.  Loss of Muscarinic Autoreceptor Function Impairs Long-Term Depression But Not Long-Term Potentiation in the Striatum , 2008, The Journal of Neuroscience.

[129]  A. Björklund,et al.  Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. , 2000, Brain : a journal of neurology.

[130]  S. Hitchcock,et al.  Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia , 2015, Neurobiology of Disease.

[131]  E. Bézard,et al.  Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets , 2004, Clinical neuropharmacology.

[132]  P. Worley,et al.  The Immediate Early Gene Arc/Arg3.1: Regulation, Mechanisms, and Function , 2008, The Journal of Neuroscience.

[133]  A. Björklund,et al.  Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease , 2012, Experimental Neurology.

[134]  A. Faure,et al.  Lesion to the Nigrostriatal Dopamine System Disrupts Stimulus-Response Habit Formation , 2005, The Journal of Neuroscience.

[135]  P. Spano,et al.  Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization , 2008, Molecular Pharmacology.

[136]  P. Jenner,et al.  Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus) , 1995, Movement disorders : official journal of the Movement Disorder Society.

[137]  K. Black,et al.  Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[138]  T. Aziz,et al.  Lesion of the subthalamic nucleus for the alleviation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism in the primate , 1991, Movement disorders : official journal of the Movement Disorder Society.

[139]  W. Yao,et al.  Dopaminergic signaling in dendritic spines. , 2008, Biochemical pharmacology.

[140]  D. Firsov,et al.  Molecular cloning of two rat GRK6 splice variants. , 1997, The American journal of physiology.

[141]  G. Gerhardt,et al.  Striatal Glutamate Release in l-DOPA-Induced Dyskinetic Animals , 2013, PloS one.

[142]  E. Snyder,et al.  Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[143]  A. Bastian Learning to predict the future: the cerebellum adapts feedforward movement control , 2006, Current Opinion in Neurobiology.

[144]  M. Morelli,et al.  Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression , 2010, Experimental Neurology.

[145]  A. Björklund,et al.  Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. , 2005, Brain : a journal of neurology.

[146]  A. Benabid,et al.  De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat , 2009, Neurobiology of Disease.

[147]  Ji-Kyung Choi,et al.  In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias , 2007, Neurobiology of Disease.

[148]  A. Benabid,et al.  Deep brain stimulation , 2004, Cell and Tissue Research.

[149]  J. Langston,et al.  Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey , 2002, Neuroscience.

[150]  D. Sulzer,et al.  Presynaptic effects of levodopa and their possible role in dyskinesia , 2015, Movement disorders : official journal of the Movement Disorder Society.

[151]  P. Seeman Brain dopamine receptors. , 1980, Pharmacological reviews.

[152]  A. Lang,et al.  Prospective prevalence of pathologic gambling and medication association in Parkinson disease , 2006, Neurology.

[153]  Thomas Boraud,et al.  Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function , 2003, Nature Medicine.

[154]  V. Gurevich,et al.  The Nature of the Arrestin·Receptor Complex Determines the Ultimate Fate of the Internalized Receptor* , 2003, The Journal of Biological Chemistry.

[155]  S. A. O. Lim,et al.  Enhanced striatal cholinergic neuronal activity mediates l-DOPA–induced dyskinesia in parkinsonian mice , 2010, Proceedings of the National Academy of Sciences.

[156]  J. Violin,et al.  β-Arrestin-biased ligands at seven-transmembrane receptors , 2007 .

[157]  G. Arbuthnott,et al.  Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age , 1989, Brain Research.

[158]  M. Caron,et al.  beta-Arrestin: a protein that regulates beta-adrenergic receptor function. , 1990, Science.

[159]  V. V. Gurevich,et al.  l-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain , 2005, Neurobiology of Disease.

[160]  I. Melnikova,et al.  Targeting protein kinases , 2004, Nature Reviews Drug Discovery.

[161]  S. Iversen,et al.  Characterisation of dyskinesias induced byl-dopa in MPTP-treated squirrel monkeys , 2005, Psychopharmacology.

[162]  Paul Greengard,et al.  Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors , 2010, Proceedings of the National Academy of Sciences.

[163]  P. Stanzione,et al.  Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[164]  Qin Li,et al.  RGS9–2 Negatively Modulates l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Experimental Parkinson's Disease , 2007, The Journal of Neuroscience.

[165]  C. Marsden,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.

[166]  P. Greengard,et al.  Resource Application of a Translational Profiling Approach for the Comparative Analysis of CNS Cell Types , 2009 .

[167]  Nikolaus R. McFarland,et al.  Striatonigrostriatal Pathways in Primates Form an Ascending Spiral from the Shell to the Dorsolateral Striatum , 2000, The Journal of Neuroscience.

[168]  P. Bédard,et al.  Primate Models of Parkinson’s Disease , 1992 .

[169]  L. Golbe Young‐onset Parkinson's disease , 1991, Neurology.

[170]  T. Chase,et al.  Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD , 2005, Experimental Neurology.

[171]  L. Tremblay,et al.  Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism , 1991, Brain Research.

[172]  J. Lindstrom,et al.  Long-Term Nicotine Treatment Decreases Striatal α6* Nicotinic Acetylcholine Receptor Sites and Function in Mice , 2005, Molecular Pharmacology.

[173]  M. Savasta,et al.  Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease , 2013, Molecular Psychiatry.

[174]  Charles J. Wilson,et al.  Cholinergic interneuron characteristics and nicotinic properties in the striatum. , 2002, Journal of neurobiology.

[175]  M. Leibowitz,et al.  Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease , 1975, Neurology.

[176]  F. Menniti,et al.  The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease , 2004, Experimental Neurology.

[177]  E. Bézard,et al.  Subthalamic stimulation elicits hemiballismus in normal monkey , 1997, Neuroreport.

[178]  J. Dostrovsky,et al.  Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. , 2000, Annals of neurology.

[179]  P. Jenner,et al.  De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset , 1998, Movement disorders : official journal of the Movement Disorder Society.

[180]  W. Tischmeyer,et al.  Activation of immediate early genes and memory formation , 1999, Cellular and Molecular Life Sciences CMLS.

[181]  R. Andrade,et al.  Molecular characterization of human and rat RGS 9L, a novel splice variant enriched in dopamine target regions, and chromosomal localization of the RGS 9 gene. , 1998, Molecular pharmacology.

[182]  D. Jacobowitz,et al.  Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. , 1984, Psychopharmacology bulletin.

[183]  Qin Li,et al.  Lentiviral Overexpression of GRK6 Alleviates l-Dopa–Induced Dyskinesia in Experimental Parkinson’s Disease , 2010, Science Translational Medicine.

[184]  Serge H. Ahmed,et al.  A Choice‐Based Screening Method for Compulsive Drug Users in Rats , 2013, Current protocols in neuroscience.

[185]  E. Hirsch,et al.  Blood vessels change in the mesencephalon of patients with Parkinson's disease , 1999, The Lancet.

[186]  P. Cortelli,et al.  Pharmacodynamic modeling of oral levodopa , 1993, Neurology.

[187]  A. Lees,et al.  Low dose quetiapine for drug induced dyskinesias in Parkinson’s disease: a double blind cross over study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[188]  H. Walter,et al.  When benefitting a patient increases the risk for harm for third persons - the case of treating pedophilic Parkinsonian patients with deep brain stimulation. , 2014, International journal of law and psychiatry.

[189]  J. Brotchie,et al.  Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[190]  Marc Parmentier,et al.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor , 1995, Nature.

[191]  T. Napier,et al.  Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls , 2012, Behavioural Brain Research.

[192]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[193]  O. Hornykiewicz,et al.  Der L-Dioxyphenylalanin (=L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: Zur Pathogenese und Behandlung der Parkinson-Akinese , 2004, Archiv für Psychiatrie und Nervenkrankheiten.

[194]  E. Bézard,et al.  Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease , 2005, Neuropharmacology.

[195]  Daniel S. McGehee,et al.  Striatal cholinergic interneuron regulation and circuit effects , 2014, Front. Synaptic Neurosci..

[196]  P. Greengard,et al.  Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia , 2014, Proceedings of the National Academy of Sciences.

[197]  J. Changeux,et al.  Nicotine enhances intracellular nicotinic receptor maturation: A novel mechanism of neural plasticity? , 2006, Journal of Physiology-Paris.

[198]  P. Sokoloff,et al.  Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions , 1998, The European journal of neuroscience.

[199]  J. Brotchie,et al.  The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[200]  H. Matthes,et al.  Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells , 1998, Journal of Neuroimmunology.

[201]  J. Powell,et al.  Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[202]  F. Monsma,et al.  Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[203]  E. Bézard,et al.  Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[204]  S. Duty,et al.  Brain Morphometry and the Neurobiology of Levodopa-Induced Dyskinesias: Current Knowledge and Future Potential for Translational Pre-Clinical Neuroimaging Studies , 2014, Front. Neurol..

[205]  P. Tuite,et al.  Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) , 2008, Annals of neurology.

[206]  C. Gotti,et al.  Subunit Composition of Nicotinic Receptors in Monkey Striatum: Effect of Treatments with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine or l-DOPA , 2005, Molecular Pharmacology.

[207]  Xuechu Zhen,et al.  Activation of Extracellular Signal-Regulated Protein Kinases Is Associated with a Sensitized Locomotor Response to D2Dopamine Receptor Stimulation in Unilateral 6-Hydroxydopamine-Lesioned Rats , 2000, The Journal of Neuroscience.

[208]  J. P. Huston,et al.  UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF MESO-STRIATAL DOPAMINE NEURONS AND THEIR PHYSIOLOGICAL SEQUELAE , 1996, Progress in Neurobiology.

[209]  Abdelhamid Benazzouz,et al.  Noradrenaline and Parkinson's Disease , 2011, Front. Syst. Neurosci..

[210]  Anatol C. Kreitzer,et al.  Striatal Plasticity and Basal Ganglia Circuit Function , 2008, Neuron.

[211]  L. Grégoire,et al.  Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias , 2010, Neuroscience.

[212]  P. Bédard,et al.  Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. , 1993, Clinical neuropharmacology.

[213]  R. Gainetdinov,et al.  Muscarinic Supersensitivity and Impaired Receptor Desensitization in G Protein–Coupled Receptor Kinase 5–Deficient Mice , 1999, Neuron.

[214]  G. Engberg A metabolite of buspirone increases locus coeruleus activity via alpha2-receptor blockade , 2005, Journal of Neural Transmission.

[215]  B. Neustadt,et al.  Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression , 2009, Journal of Pharmacology and Experimental Therapeutics.

[216]  M. Cenci,et al.  Ratings of L‐DOPA‐Induced Dyskinesia in the Unilateral 6‐OHDA Lesion Model of Parkinson's Disease in Rats and Mice , 2007, Current protocols in neuroscience.

[217]  M. Andersson,et al.  Alterations in Cortical and Basal Ganglia Levels of Opioid Receptor Binding in a Rat Model of l -DOPA-Induced Dyskinesia , 2001, Neurobiology of Disease.

[218]  Susan H Fox,et al.  Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson’s disease , 2003, Experimental Neurology.

[219]  E. Gurevich,et al.  Sex differences in the activity of signalling pathways and expression of G-protein-coupled receptor kinases in the neonatal ventral hippocampal lesion model of schizophrenia. , 2011, The international journal of neuropsychopharmacology.

[220]  G. Linazasoro Anticholinergics and dyskinesia. , 1994, Movement disorders : official journal of the Movement Disorder Society.

[221]  N. Mercuri,et al.  Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice , 2014, Experimental Neurology.

[222]  Eduardo E. Benarroch,et al.  Locus coeruleus , 2017, Cell and Tissue Research.

[223]  A. Lees,et al.  Anticholinergics for symptomatic management of Parkinson's disease. , 2002, The Cochrane database of systematic reviews.

[224]  R. Lefkowitz,et al.  Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[225]  P. Calabresi,et al.  Unilateral dopamine denervation blocks corticostriatal LTP. , 1999, Journal of neurophysiology.

[226]  R. Katzenschlager,et al.  Punding and dyskinesias , 2006, Movement disorders : official journal of the Movement Disorder Society.

[227]  C. Adler,et al.  Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. , 1998, Archives of neurology.

[228]  J. D. Parkes,et al.  Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .

[229]  Paul Greengard,et al.  DARPP-32: Regulator of the Efficacy of Dopaminergic Neurotransmission , 1998 .

[230]  J. Girault,et al.  Gene Expression Analyses Identify Narp Contribution in the Development of l-DOPA-Induced Dyskinesia , 2015, The Journal of Neuroscience.

[231]  A. Lang,et al.  Punding prevalence in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[232]  D. Charvin,et al.  A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine core. , 2013, Bioorganic & medicinal chemistry letters.

[233]  P. Blier,et al.  Autoregulation of serotonin neurons: role in antidepressant drug action. , 1999, Pharmacological reviews.

[234]  J M Willets,et al.  Selective Reduction in A2 Adenosine Receptor Desensitization Following Antisense‐Induced Suppression of G Protein‐Coupled Receptor Kinase 2 Expression , 1999, Journal of neurochemistry.

[235]  E. Bézard,et al.  Experimental Models of Parkinson's Disease: From the Static to the Dynamic , 1998, Reviews in the neurosciences.

[236]  C. Clarke,et al.  A Randomized, Double-blind, Placebo-controlled, Ascending-dose Tolerability and Safety Study of Remacemide as Adjuvant Therapy in Parkinson's Disease with Response Fluctuations , 2001, Clinical neuropharmacology.

[237]  Qin Li,et al.  A critique of available scales and presentation of the non‐human primate dyskinesia rating scale , 2012, Movement disorders : official journal of the Movement Disorder Society.

[238]  G. Rylander Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. , 1972, Psychiatria, neurologia, neurochirurgia.

[239]  J. C. Stoof,et al.  Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum , 1981, Nature.

[240]  D. Choquet,et al.  NMDA receptor surface mobility depends on NR2A-2B subunits , 2006, Proceedings of the National Academy of Sciences.

[241]  Kuei Yuan Tseng,et al.  Aberrant Restoration of Spines and their Synapses in l-DOPA-Induced Dyskinesia: Involvement of Corticostriatal but Not Thalamostriatal Synapses , 2013, The Journal of Neuroscience.

[242]  A. Björklund,et al.  The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study , 2015, Neurobiology of Aging.

[243]  R. Franco,et al.  l-DOPA disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies , 2014, Experimental Neurology.

[244]  T. Di Paolo,et al.  Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. , 1997, Brain research. Molecular brain research.

[245]  J. Labandeira-Garcia,et al.  Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β , 2014, Experimental Neurology.

[246]  J. Langston,et al.  The selective κ-opioid receptor agonist U50,488 reduces l-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates , 2007, Experimental Neurology.

[247]  J. Dostrovsky,et al.  Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia , 2014, Neurobiology of Disease.

[248]  P. Stanzione,et al.  Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations , 2013, Movement disorders : official journal of the Movement Disorder Society.

[249]  Erwan Bezard,et al.  Phenotype of Striatofugal Medium Spiny Neurons in Parkinsonian and Dyskinetic Nonhuman Primates: A Call for a Reappraisal of the Functional Organization of the Basal Ganglia , 2006, The Journal of Neuroscience.

[250]  P. Danielson,et al.  Embryonic mesencephalic grafts increase levodopa‐induced forelimb hyperkinesia in parkinsonian rats , 2003, Movement disorders : official journal of the Movement Disorder Society.

[251]  N. Mercuri,et al.  Blockade of Nociceptin/orphanin Fq Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior ,lys 15 ]n/ofq(1–13)-nh 2 ) (a Selective Nop Receptor Peptide Antagonist) Stimulated It. N/ofq Microinjected in the Sub- Stantia Nigra P , 2022 .

[252]  Arnaud H. Muller,et al.  Central and peripheral endogenous morphine , 2009 .

[253]  D B Calne,et al.  Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. , 1991, Archives of neurology.

[254]  P. Andrén,et al.  Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease. , 2005, Journal of mass spectrometry : JMS.

[255]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.

[256]  P. Brundin,et al.  Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats , 2009, Experimental Neurology.

[257]  J. Brotchie,et al.  μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease , 2001, Experimental Neurology.

[258]  P. Calabresi,et al.  l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation , 2008, Neurobiology of Disease.

[259]  Dinesh Kumar,et al.  Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. , 2004, British journal of clinical pharmacology.

[260]  T. Suda,et al.  Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. , 1999, Neuroreport.

[261]  F. Pedata,et al.  Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. , 2002, European journal of pharmacology.

[262]  M. Besson,et al.  Involvement of the Extracellular Signal-Regulated Kinase Cascade for Cocaine-Rewarding Properties , 2000, The Journal of Neuroscience.

[263]  R. Hauser,et al.  Double‐blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[264]  M. Fälth,et al.  l-DOPA-induced Dyskinesia is Associated with Regional Increase of Striatal Dynorphin Peptides as Elucidated by Imaging Mass Spectrometry , 2011, Molecular & Cellular Proteomics.

[265]  K. E Bridge,et al.  Autoradiographic localization of 125i[tyr14] nociceptin/orphanin fq binding sites in macaque primate cns , 2003, Neuroscience.

[266]  P. Calabresi,et al.  Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia , 2015, Biological Psychiatry.

[267]  P. Frankland,et al.  Uncoupling the D1-N-Methyl-D-Aspartate (NMDA) Receptor Complex Promotes NMDA-Dependent Long-Term Potentiation and Working Memory , 2010, Biological Psychiatry.

[268]  B. Långström,et al.  Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET , 1996, Neurology.

[269]  Y. Goshima,et al.  l-DOPA systems for blood pressure regulation in the lower brainstem , 1995, Neuroscience Research.

[270]  John R. Adams,et al.  Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. , 2005, Brain research. Molecular brain research.

[271]  R. Hen,et al.  G(olf)alpha mediates dopamine D1 receptor signaling. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[272]  E. Shiorring Psychopathology induced by 'speed' drugs - (amphetamine, cocaine and related compounds) , 1980 .

[273]  D Oakes,et al.  Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease , 2003, Experimental Neurology.

[274]  Maxime Dahan,et al.  Transient directed motions of GABA(A) receptors in growth cones detected by a speed correlation index. , 2007, Biophysical journal.

[275]  J. Parkinson An Essay on the Shaking Palsy , 2002 .

[276]  L. Grégoire,et al.  AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. , 2014, Parkinsonism & related disorders.

[277]  S. R. Nash,et al.  Differential Regulation of Dopamine D1A Receptor Responsiveness by Various G Protein-coupled Receptor Kinases (*) , 1996, The Journal of Biological Chemistry.

[278]  Antonio Cerasa,et al.  A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias. , 2015, Brain : a journal of neurology.

[279]  K. Shannon,et al.  Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats , 2006, Neurobiology of Disease.

[280]  Suzanne N Haber,et al.  Dopamine Replacement Therapy Does Not Restore the Full Spectrum of Normal Pallidal Activity in the 1-Methyl-4-Phenyl-1,2,3,6-Tetra-Hydropyridine Primate Model of Parkinsonism , 2006, The Journal of Neuroscience.

[281]  Marios Politis,et al.  Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.

[282]  O. Hornykiewicz,et al.  Functional sensitization of striatal dopamine D1 receptors in the 6-hydroxydopamine-lesioned rat , 1992, Brain Research.

[283]  O. Blin,et al.  Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.

[284]  P. Seeman,et al.  Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata , 1993, Synapse.

[285]  M Schulzer,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.

[286]  P. Brown,et al.  Beta band stability over time correlates with Parkinsonian rigidity and bradykinesia , 2012, Experimental Neurology.

[287]  P. D. Blasi,et al.  Repetitive transcranial magnetic stimulation transiently reduces punding in Parkinson’s disease: a preliminary study , 2013, Journal of Neural Transmission.

[288]  G. Nikkhah,et al.  Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation , 2011, Experimental Neurology.

[289]  M. Davie Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. , 2007, The Journal of neuropsychiatry and clinical neurosciences.

[290]  J. Welge,et al.  Genotype and smoking history affect risk of levodopa‐induced dyskinesias in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[291]  G Vassart,et al.  ORL1, a novel member of the opioid receptor family , 1994, FEBS letters.

[292]  Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats , 2011, Psychopharmacology.

[293]  Erwan Bezard,et al.  Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders , 2009, The Lancet Neurology.

[294]  P. Jenner,et al.  Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets , 2002, Neuroscience.

[295]  E. Nestler,et al.  Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. , 2001, Biological psychiatry.

[296]  Andrew J Lees,et al.  Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series , 2007, Movement disorders : official journal of the Movement Disorder Society.

[297]  T. Sotnikova,et al.  The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment , 2012, Scientific Reports.

[298]  T. Shippenberg,et al.  Differential involvement of D1 and D2 dopamine receptors in the expression of morphine withdrawal signs in rats. , 1996, Behavioural pharmacology.

[299]  P. Derambure,et al.  Effect of dopaminergic substances on sleep/wakefulness in saline‐ and MPTP‐treated mice , 2008, Journal of sleep research.

[300]  A. Benazzouz,et al.  MPTP induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies , 2004, Experimental Brain Research.

[301]  E. Tolosa,et al.  Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial , 2007, The Lancet Neurology.

[302]  S. Baader,et al.  Dynamics of beta2-adrenergic receptor-ligand complexes on living cells. , 2004, Biochemistry.

[303]  Werner Poewe,et al.  Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 , 2005, Movement disorders : official journal of the Movement Disorder Society.

[304]  K. Steece-Collier,et al.  Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats , 2009, The Journal of comparative neurology.

[305]  M. Mimura,et al.  Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial , 2012, Journal of the Neurological Sciences.

[306]  J. Joyce Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system , 1991, Experimental Neurology.

[307]  B. Bioulac,et al.  Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease , 2011, Neurobiology of Disease.

[308]  S. Konitsiotis,et al.  Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[309]  G. Meco,et al.  Buspirone in levodopa-induced dyskinesias. , 1994, Clinical neuropharmacology.

[310]  ChristopheGuignabert,et al.  Serotonin Transporter Inhibition Prevents and Reverses Monocrotaline-Induced Pulmonary Hypertension in Rats , 2005 .

[311]  P. Fischer,et al.  The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. , 2004, Current medicinal chemistry.

[312]  M. Geffard,et al.  Baroreceptor-aortic nerve-mediated release of endogenous L-3,4-dihydroxyphenylalanine and its tonic depressor function in the nucleus tractus solitarii of rats , 1994, Neuroscience.

[313]  J. Woods,et al.  Drug and Reinforcement History as Determinants of the Response-Maintaining Effects of Quinpirole in the Rat , 2007, Journal of Pharmacology and Experimental Therapeutics.

[314]  Qin Li,et al.  Permeability of blood–brain barrier in macaque model of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced Parkinson disease , 2016, Synapse.

[315]  G. Deuschl,et al.  A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.

[316]  D. Riche,et al.  Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in parkinson's disease , 1994, Neuroscience.

[317]  Hideki Oshima,et al.  Direct Effect of Subthalamic Nucleus Stimulation on Levodopa-Induced Peak-Dose Dyskinesia in Patients with Parkinson’s Disease , 2006, Stereotactic and Functional Neurosurgery.

[318]  T. Dalkara,et al.  Compartmental changes in expression of c-Fos and FosB proteins in intact and dopamine-depleted striatum after chronic apomorphine treatment , 1999, Brain Research.

[319]  B. Cox,et al.  Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats , 2009, Neuropharmacology.

[320]  A. Quattrone,et al.  Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. , 1999, Neurology.

[321]  Erwan Bezard,et al.  Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies , 2001, Nature Reviews Neuroscience.

[322]  Ji-Kyung Choi,et al.  Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling , 2006, NeuroImage.

[323]  H. Koh,et al.  Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats , 2011, Brain Research Bulletin.

[324]  E. Bézard,et al.  Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracelullar striatal dopamine , 2006, Neurobiology of Disease.

[325]  A. Destée,et al.  Withdrawing amantadine in dyskinetic patients with Parkinson disease , 2014, Neurology.

[326]  M. Cenci,et al.  The “motor complication syndrome” in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration , 2007, Behavioural Brain Research.

[327]  R. Mach,et al.  Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.

[328]  H. Akil,et al.  Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study , 1994, The Journal of comparative neurology.

[329]  H. Putter,et al.  Risk factors for hallucinations in Parkinson's disease: Results from a large prospective cohort study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[330]  Daniel Choquet,et al.  Direct imaging of lateral movements of AMPA receptors inside synapses , 2003, The EMBO journal.

[331]  P. Salin,et al.  Forelimb dyskinesia mediated by high‐frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N‐methyl‐d‐aspartate receptors , 2010, The European journal of neuroscience.

[332]  Riccardo Viaro,et al.  Nociceptin/Orphanin FQ Modulates Motor Behavior and Primary Motor Cortex Output Through Receptors Located in Substantia Nigra Reticulata , 2009, Neuropsychopharmacology.

[333]  P. Brodal,et al.  The projection from the nucleus reticularis tegmenti pontis to the cerebellum in the rhesus monkey , 2004, Experimental Brain Research.

[334]  Vesna Sossi,et al.  Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[335]  U. Bonuccelli,et al.  Serotonergic antidepressant drugs and L‐dopa‐induced dyskinesias in Parkinson's disease , 2015, Acta neurologica Scandinavica.

[336]  Niall P Quinn,et al.  Reckless generosity in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[337]  W. Hall,et al.  Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. , 2011, Addiction.

[338]  Simon Hong,et al.  The Globus Pallidus Sends Reward-Related Signals to the Lateral Habenula , 2008, Neuron.

[339]  I. Mitchell,et al.  A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. , 1992, Brain : a journal of neurology.

[340]  A. Björklund,et al.  Dyskinesias following neural transplantation in Parkinson's disease , 2002, Nature Neuroscience.

[341]  M. Trimble,et al.  The Lateral Habenula: No Longer Neglected , 2008, CNS Spectrums.

[342]  M. Cenci L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. , 2007, Parkinsonism & related disorders.

[343]  Y. Wong,et al.  The ORL1 Receptor: Molecular Pharmacology and Signalling Mechanisms , 2002, Neurosignals.

[344]  L. Tremblay,et al.  A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. , 2007, Brain : a journal of neurology.

[345]  F. Grandas,et al.  Risk factors for levodopa-induced dyskinesias in Parkinson’s disease , 1999, Journal of Neurology.

[346]  F. Turkheimer,et al.  Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. , 2014, The Journal of clinical investigation.

[347]  Mark Hallett,et al.  Impulsive choice and response in dopamine agonist-related impulse control behaviors , 2009, Psychopharmacology.

[348]  G. Di Chiara,et al.  Changes in the D1 receptor-adenylate cyclase complex after priming. , 1990, European journal of pharmacology.

[349]  P. Calabresi,et al.  Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. , 2005, Neurotoxicology.

[350]  A. Björklund,et al.  Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. , 2008, Brain : a journal of neurology.

[351]  E. Albuquerque,et al.  Mammalian nicotinic acetylcholine receptors: from structure to function. , 2009, Physiological reviews.

[352]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[353]  R. Depoortère,et al.  NLX-112, a novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat , 2015, Experimental Neurology.

[354]  Erwan Bezard,et al.  Involvement of Sensorimotor, Limbic, and Associative Basal Ganglia Domains in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia , 2005, The Journal of Neuroscience.

[355]  A. Stoessl Central pharmacokinetics of levodopa: Lessons from imaging studies , 2015, Movement disorders : official journal of the Movement Disorder Society.

[356]  A. Lang,et al.  Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. , 2007, Archives of neurology.

[357]  Duvoisin Rc Variations in the "on-off" phenomenon. , 1974 .

[358]  M. Merello,et al.  Apomorphine induces changes in GPi spontaneous outflow in patients with parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[359]  J. P. Huston,et al.  The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments , 1996, Progress in Neurobiology.

[360]  J. Benovic,et al.  Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia , 2008, Neurobiology of Aging.

[361]  P. Brodal,et al.  The pontocerebellar projection in the rhesus monkey: An experimental study with retrograde axonal transport of horseradish peroxidase , 1979, Neuroscience.

[362]  E. Bézard,et al.  D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly , 2015, Neurobiology of Disease.

[363]  G. Deuschl,et al.  Surgical treatment of Parkinson's disease. , 1999, Current opinion in neurology.

[364]  P. Calabresi,et al.  Long-term synaptic depression in the striatum: physiological and pharmacological characterization , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[365]  A. Aristieta,et al.  The locus coeruleus Is Directly Implicated in L-DOPA-Induced Dyskinesia in Parkinsonian Rats: An Electrophysiological and Behavioural Study , 2011, PloS one.

[366]  M. Cenci,et al.  Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse. , 2014, Parkinsonism & related disorders.

[367]  M. Morari,et al.  RAPID COMMUNICATION: Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol‐induced akinesia and normalizes nigral glutamate release , 2004, Journal of neurochemistry.

[368]  W. Hall,et al.  Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction? , 2012, Addiction.

[369]  A. Lang,et al.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.

[370]  D. Eidelberg,et al.  Effects of levodopa on regional cerebral metabolism and blood flow , 2015, Movement disorders : official journal of the Movement Disorder Society.

[371]  J. Liebman,et al.  Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys , 1983, Psychopharmacology.

[372]  O. Hornykiewicz,et al.  Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa‐induced motor complications , 2003, Movement disorders : official journal of the Movement Disorder Society.

[373]  P. Deyn,et al.  Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care , 2013, Journal of Neural Transmission.

[374]  M. Millan,et al.  Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. , 1997, Journal of neurochemistry.

[375]  R. Hauser,et al.  Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients , 2016, The International journal of neuroscience.

[376]  A. Destée,et al.  AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[377]  P. Ravenscroft,et al.  Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia , 2013, Experimental Neurology.

[378]  J. Yamada,et al.  Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia , 2014, Neurobiology of Disease.

[379]  R. Moratalla,et al.  Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3−/− aphakia mice , 2015, Neurobiology of Disease.

[380]  A. J. Stoessl,et al.  Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations , 2000, Journal of Neural Transmission.

[381]  G. Di Chiara,et al.  Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. , 1989, European journal of pharmacology.

[382]  M. Mellone,et al.  Modulation of NMDA receptor at the synapse: promising therapeutic interventions in disorders of the nervous system. , 2013, European journal of pharmacology.

[383]  Qin Li,et al.  Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates , 2007, Neurobiology of Disease.

[384]  J. Salamone,et al.  Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. , 2008, Frontiers in bioscience : a journal and virtual library.

[385]  E. Tronci,et al.  Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease , 2012, Parkinson's disease.

[386]  S. Salvadori,et al.  Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease , 2005, The Journal of Neuroscience.

[387]  H. Ehringer,et al.  Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems , 2005, Klinische Wochenschrift.

[388]  M. Trulson,et al.  Dopamine neuron transplants: electrophysiological unit activity of intrastriatal nigral grafts in freely moving cats. , 1987, Life sciences.

[389]  L. Wilkins Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study , 2007, Neurology.

[390]  A. Benabid,et al.  Coordinated and Spatial Upregulation of Arc in Striatonigral Neurons Correlates With L-Dopa-Induced Behavioral Sensitization in Dyskinetic Rats , 2005, Journal of neuropathology and experimental neurology.

[391]  T. Chase,et al.  Dietary influences on the antiparkinsonian response to levodopa. , 1987, Archives of neurology.

[392]  B. Bioulac,et al.  MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study , 1985, Brain Research.

[393]  M. Millan,et al.  Actions at sites other than D3 receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats , 2006, Experimental Neurology.

[394]  J. Nutt,et al.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. , 2002, Archives of neurology.

[395]  T. Lamb,et al.  The Gain of Rod Phototransduction Reconciliation of Biochemical and Electrophysiological Measurements , 2000, Neuron.

[396]  A. Björklund,et al.  Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. , 2008, Progress in brain research.

[397]  T. Svensson,et al.  Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias , 2010, Experimental Neurology.

[398]  M. Morelli,et al.  Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6‐hydroxydopamine‐lesioned rats , 2003, The European journal of neuroscience.

[399]  L. Descarries,et al.  Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia , 2010, Annals of neurology.

[400]  C. Barnum,et al.  Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat , 2008, Neuropharmacology.

[401]  M. Hallett,et al.  Dopamine agonists and risk: impulse control disorders in Parkinson's disease. , 2011, Brain : a journal of neurology.

[402]  A. Grace,et al.  Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[403]  M. Besson,et al.  Cortical and nigral deafferentation and striatal cholinergic markers in the rat dorsal striatum: different effects on the expression of mRNAs encoding choline acetyltransferase and muscarinic m1 and m4 receptors , 1999, The European journal of neuroscience.

[404]  P. Braga-Neto,et al.  Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. , 2005, Parkinsonism & related disorders.

[405]  G. Pozzessere,et al.  Low dosage clozapine effects on L‐dopa induced dyskinesias in parkinsonian patients , 1998, Acta neurologica Scandinavica.

[406]  J. Matsumoto,et al.  Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. , 2005, Parkinsonism & related disorders.

[407]  J. Tepper,et al.  Electrophysiological characteristics of cells within mesencephalon suspension grafts , 1991, Neuroscience.

[408]  D. Kirik,et al.  Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA–induced dyskinesia in rats , 2010, Proceedings of the National Academy of Sciences.

[409]  J M Smith,et al.  Compulsive buying: a report of 20 cases. , 1994, The Journal of clinical psychiatry.

[410]  Paola Piccini,et al.  Priorities in Parkinson's disease research , 2011, Nature Reviews Drug Discovery.

[411]  Famotidine, a Histamine H2 Receptor Antagonist, Does Not Reduce Levodopa‐Induced Dyskinesia in Parkinson's Disease: A Proof‐of‐Concept Study , 2014, Movement disorders clinical practice.

[412]  C. Missale,et al.  Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease , 2013, Neurobiology of Disease.

[413]  P. Gubellini,et al.  Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia , 2013, Neuropharmacology.

[414]  Andrew J Lees,et al.  Excessive hoarding in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[415]  Mark Stacy,et al.  Clinical spectrum of impulse control disorders in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[416]  E. Bézard,et al.  Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. , 2005, Parkinsonism & related disorders.

[417]  P. Blanchet,et al.  Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients , 1999, Neurology.

[418]  Thomas H. McNeill,et al.  Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease , 1988, Brain Research.

[419]  Tejas Sankar,et al.  Magnetic resonance imaging and deep brain stimulation. , 2011, Journal of neurosurgery.

[420]  D. Mash,et al.  Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. , 2001, Brain research. Molecular brain research.

[421]  L. Seeberger,et al.  A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease , 2001, Neurology.

[422]  H. Kennedy,et al.  Early Presymptomatic and Long-Term Changes of Rest Activity Cycles and Cognitive Behavior in a MPTP-Monkey Model of Parkinson's Disease , 2011, PloS one.

[423]  L. Defebvre,et al.  Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[424]  I. Mitchell,et al.  Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus , 1985, Neuroscience Letters.

[425]  L. Tremblay,et al.  Behavioral Recovery in MPTP-Treated Monkeys: Neurochemical Mechanisms Studied by Intrastriatal Microdialysis , 2008, The Journal of Neuroscience.

[426]  P. Christos,et al.  Prospective cohort study of impulse control disorders in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[427]  A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease , 2005, Experimental Neurology.

[428]  J. Bronstein,et al.  Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease , 2006, Neurology.

[429]  H. Russmann,et al.  Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years , 2004, Neurology.

[430]  W. Ondo,et al.  Predictors of impulsivity and reward seeking behavior with dopamine agonists. , 2008, Parkinsonism & related disorders.

[431]  C. Colosimo,et al.  Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[432]  F. Guimarães,et al.  Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. , 2004, European journal of pharmacology.

[433]  M. Cenci,et al.  Rodent models of treatment-induced motor complications in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[434]  E. Lane,et al.  l-DOPA and graft-induced dyskinesia: Different treatment, same story? , 2013, Experimental biology and medicine.

[435]  Alexander Hammers,et al.  Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. , 2011, Brain : a journal of neurology.

[436]  S. Schiffmann,et al.  Distribution of adenosine A2 receptor mRNA in the human brain , 1991, Neuroscience Letters.

[437]  O. Hornykiewicz,et al.  Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. , 2004, Brain : a journal of neurology.

[438]  Gabriel M. Belfort,et al.  Npas4 Regulates a Transcriptional Program in CA3 Required for Contextual Memory Formation , 2011, Science.

[439]  M. Cenci,et al.  Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease , 2009, Neuropsychopharmacology.

[440]  Marc G Caron,et al.  Identification of PSD-95 as a Regulator of Dopamine-Mediated Synaptic and Behavioral Plasticity , 2004, Neuron.

[441]  M. Savasta,et al.  Subthalamic Stimulation-Induced Forelimb Dyskinesias Are Linked to an Increase in Glutamate Levels in the Substantia Nigra Pars Reticulata , 2006, The Journal of Neuroscience.

[442]  R. Alterman,et al.  Immediate and sustained relief of levodopa-induced dyskinesias after dorsal relocation of a deep brain stimulation lead. Case report. , 2004, Neurosurgical focus.

[443]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[444]  P. Magistretti,et al.  Metabolic coupling between glia and neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[445]  J. Kordower,et al.  Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson’s disease , 2008, Neurobiology of Disease.

[446]  Arun Singh,et al.  Dual κ‐agonist/μ‐antagonist opioid receptor modulation reduces levodopa‐induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease , 2015, Annals of neurology.

[447]  David Belin,et al.  Evidence for Addiction-like Behavior in the Rat , 2004, Science.

[448]  E. Gatto,et al.  Kleptomania, an unusual impulsive control disorder in Parkinson's disease? , 2010, Parkinsonism & related disorders.

[449]  R. Kaji,et al.  Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[450]  L. Grégoire,et al.  Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys , 2010, Neuropharmacology.

[451]  N. Hattori,et al.  [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[452]  G. Deuschl,et al.  Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) , 2002, Acta neurologica Scandinavica.

[453]  H. Reichmann,et al.  Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials , 2014, European journal of neurology.

[454]  J. Benovic,et al.  Mechanism of Quenching of Phototransduction , 1997, The Journal of Biological Chemistry.

[455]  Brice de la Crompe,et al.  Inhibiting Lateral Habenula Improves L-DOPA–Induced Dyskinesia , 2016, Biological Psychiatry.

[456]  H. Loh,et al.  Molecular mechanisms and regulation of opioid receptor signaling. , 2000, Annual review of pharmacology and toxicology.

[457]  Robert E. Kingston,et al.  Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. , 2013, Molecular cell.

[458]  J. Brotchie,et al.  Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study , 2001, Neurology.

[459]  G. Gerhardt,et al.  Serotonergic nerve fibers in l-DOPA-derived dopamine release and dyskinesia , 2014, Neuroscience.

[460]  A. Lawrence,et al.  Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? , 2003, The Lancet Neurology.

[461]  A. Schrag,et al.  Low-dose olanzapine for levodopa induced dyskinesias , 2000, Neurology.

[462]  M. Andersson,et al.  Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease , 2001, The European journal of neuroscience.

[463]  P. Calabresi,et al.  A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression , 1999, The Journal of Neuroscience.

[464]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[465]  A. Strafella,et al.  Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[466]  P. Greengard,et al.  DARPP-32 mediates serotonergic neurotransmission in the forebrain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[467]  F. Fadda,et al.  Role of striatal l‐DOPA in the production of dyskinesia in 6‐hydroxydopamine lesioned rats , 2006, Journal of neurochemistry.

[468]  Qin Li,et al.  Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. , 2007, Neurobiology of disease.

[469]  M. Decker,et al.  The α7 Nicotinic Receptor Agonist ABT-107 Decreases l-Dopa–Induced Dyskinesias in Parkinsonian Monkeys , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[470]  J. Anselmo-Franci,et al.  Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats , 2015, Neuropharmacology.

[471]  L. Groc,et al.  Surface trafficking of NMDA receptors: gathering from a partner to another. , 2014, Seminars in cell & developmental biology.

[472]  J. Meerwaldt,et al.  Factors that influence the occurrence of response variations in Parkinson's disease , 1987, Annals of neurology.

[473]  A. Cerasa,et al.  Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement. , 2013, Parkinsonism & related disorders.

[474]  M. Cenci,et al.  Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications , 2014, Front. Neurol..

[475]  R. Desimone,et al.  Internal globus pallidus discharge is nearly suppressed during levodopa‐induced dyskinesias , 1999, Annals of neurology.

[476]  Danqing Xiao,et al.  Forebrain Adenosine A2A Receptors Contribute to l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Hemiparkinsonian Mice , 2006, The Journal of Neuroscience.

[477]  Hagai Bergman,et al.  Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates , 1999, Experimental Brain Research.

[478]  C. Barnum,et al.  Effects of the beta‐adrenergic receptor antagonist Propranolol on dyskinesia and L‐DOPA‐induced striatal DA efflux in the hemi‐parkinsonian rat , 2015, Journal of neurochemistry.

[479]  A. Graybiel Building action repertoires: memory and learning functions of the basal ganglia , 1995, Current Opinion in Neurobiology.

[480]  F. Monsma,et al.  Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ , 1996, Neurochemical Research.

[481]  C. Phelix,et al.  Monoamine innervation of bed nucleus of stria terminalis: An electron microscopic investigation , 1992, Brain Research Bulletin.

[482]  Erwan Bezard,et al.  Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-dopa–induced dyskinesia , 2010, Proceedings of the National Academy of Sciences.

[483]  G Baselli,et al.  Altered subthalamo-pallidal synchronisation in parkinsonian dyskinesias , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[484]  M. Contin,et al.  Pharmacokinetics of levodopa , 2010, Journal of Neurology.

[485]  P. Ravenscroft,et al.  Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[486]  Harald Binder,et al.  Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. , 2014, Parkinsonism & related disorders.

[487]  Yu Tian Wang,et al.  Dual Regulation of NMDA Receptor Functions by Direct Protein-Protein Interactions with the Dopamine D1 Receptor , 2002, Cell.

[488]  C. Gerfen,et al.  D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[489]  Regina Katzenschlager,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[490]  P. Jenner,et al.  L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations , 2001, Psychopharmacology.

[491]  I. Mitchell,et al.  Reversal of Parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: Potential mechanisms of action , 1997, Neuroscience & Biobehavioral Reviews.

[492]  I. Forgacs,et al.  Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life , 2009, Movement disorders : official journal of the Movement Disorder Society.

[493]  J. Yakel,et al.  Desensitization of nicotinic ACh receptors: shaping cholinergic signaling , 2005, Trends in Neurosciences.

[494]  T. Itoh,et al.  l-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model , 2014, Pharmacology Biochemistry and Behavior.

[495]  M. Farrer,et al.  A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[496]  Sachie K. Ogawa,et al.  Whole-Brain Mapping of Direct Inputs to Midbrain Dopamine Neurons , 2012, Neuron.

[497]  Y. Smith,et al.  Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys , 2009, Experimental Neurology.

[498]  C. McClung,et al.  DeltaFosB: a molecular switch for long-term adaptation in the brain. , 2004, Brain research. Molecular brain research.

[499]  M. Caron,et al.  Synergistic regulation of beta2-adrenergic receptor sequestration: intracellular complement of beta-adrenergic receptor kinase and beta-arrestin determine kinetics of internalization. , 1997, Molecular pharmacology.

[500]  J. Girault,et al.  Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for l-DOPA-induced dyskinesia , 2014, Neuroscience Letters.

[501]  P. Jenner,et al.  The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. , 2003, Parkinsonism & related disorders.

[502]  S. Bassett,et al.  Clinical features associated with impulse control disorders in Parkinson disease , 2006, Neurology.

[503]  M. Nirenberg,et al.  Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.

[504]  Denis Hervé,et al.  Gαolf Mutation Allows Parsing the Role of cAMP-Dependent and Extracellular Signal-Regulated Kinase-Dependent Signaling in l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia , 2012, The Journal of Neuroscience.

[505]  E. Bézard,et al.  Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey , 2000, Journal of Neuroscience Methods.

[506]  Epilepsy: from newly diagnosed to treatment-resistant disease , 2011, The Lancet Neurology.

[507]  E. Ongini,et al.  Persistent Behavioral Sensitization to Chronic l-DOPA Requires A2A Adenosine Receptors , 2002, The Journal of Neuroscience.

[508]  Y. Agid,et al.  Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[509]  O. Hornykiewicz,et al.  Sensitization of Dopamine‐Stimulated Adenylyl Cyclase in the Striatum of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Treated Rhesus Monkeys and Patients with Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.

[510]  M. Chesselet,et al.  3,4-Dihydroxyphenylalanine Reverses the Motor Deficits in Pitx3-Deficient Aphakia Mice: Behavioral Characterization of a Novel Genetic Model of Parkinson's Disease , 2005, The Journal of Neuroscience.

[511]  M. Caron,et al.  Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems. , 1992, The Journal of biological chemistry.

[512]  K. Helin,et al.  Polycomb group protein displacement and gene activation through MSK-dependent H3K27me3S28 phosphorylation. , 2010, Molecular cell.

[513]  J. Hubble Long-term studies of dopamine agonists , 2002, Neurology.

[514]  D. Weintraub,et al.  Impulse Control and Related Disorders in Parkinson's Disease. , 2017, International review of neurobiology.

[515]  M. Morelli,et al.  Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. , 2007, European journal of pharmacology.

[516]  P. Lewitt,et al.  Actively Transported Levodopa Prodrug XP21279: A Study in Patients With Parkinson Disease Who Experience Motor Fluctuations , 2012, Clinical neuropharmacology.

[517]  Steven W. Johnson,et al.  Evaluation of Levodopa Dose and Magnitude of Dopamine Depletion as Risk Factors for Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease , 2007, Journal of Pharmacology and Experimental Therapeutics.

[518]  N. Van Blercom,et al.  Effects of Gabapentin on the Motor Response to Levodopa: A Double-Blind, Placebo-Controlled, Crossover Study in Patients With Complicated Parkinson Disease , 2004, Clinical neuropharmacology.

[519]  M. Andersson,et al.  Striatal fosB Expression Is Causally Linked with l -DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease , 1999, Neurobiology of Disease.

[520]  W. Ko,et al.  Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primate model of Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[521]  D. Engblom,et al.  Mechanisms of Dopamine D1 Receptor-Mediated ERK1/2 Activation in the Parkinsonian Striatum and Their Modulation by Metabotropic Glutamate Receptor Type 5 , 2014, The Journal of Neuroscience.

[522]  S. Deacon,et al.  The challenge of selecting protein kinase assays for lead discovery optimization , 2008, Expert opinion on drug discovery.

[523]  G. Calo’,et al.  Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice , 2002, British journal of pharmacology.

[524]  M. Andersson,et al.  Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-DOPA treatment , 1999, Neuroscience.

[525]  P. Zhuang,et al.  Stimulation-Induced Dyskinesia in the Early Stage after Subthalamic Deep Brain Stimulation , 2009, Stereotactic and Functional Neurosurgery.

[526]  G. Pasternak,et al.  The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. , 2001, Pharmacological reviews.

[527]  Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease , 2013, Neuropsychiatric disease and treatment.

[528]  R. Malenka,et al.  N‐methyl‐d‐aspartate receptor‐ and metabotropic glutamate receptor‐dependent long‐term depression are differentially regulated by the ubiquitin‐proteasome system , 2009, The European journal of neuroscience.

[529]  L. Grégoire,et al.  Effect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys , 2010, Journal of neurochemistry.

[530]  C. Cepeda,et al.  Repeated Exposure to Methamphetamine Causes Long-Lasting Presynaptic Corticostriatal Depression that Is Renormalized with Drug Readministration , 2008, Neuron.

[531]  S. Houle,et al.  Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD , 2010, Neurology.

[532]  R. G. Robertson,et al.  Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1989, Neuroscience.

[533]  S. Papapetropoulos Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial , 2011 .

[534]  L. Metman,et al.  Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study , 2001, Movement disorders : official journal of the Movement Disorder Society.

[535]  D. Hansel,et al.  Physiology of MPTP Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[536]  K. Dupre,et al.  Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation , 2011, Neuropharmacology.

[537]  M. Quik,et al.  Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function , 2013, Neurobiology of Disease.

[538]  N. Sonenberg,et al.  Translational Control of Long-Lasting Synaptic Plasticity and Memory , 2009, Neuron.

[539]  J. Maloteaux,et al.  Altered expression of regulators of G-protein signaling (RGS) mRNAs in the striatum of rats undergoing dopamine depletion. , 2003, Biochemical pharmacology.

[540]  R. Pearce L-dopa and dyskinesias in normal monkeys. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[541]  J. Langston,et al.  Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. , 2004, Archives of neurology.

[542]  T. Di Paolo,et al.  Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D1 or D2 Receptor Agonists , 1999, Journal of neurochemistry.

[543]  C. Gerfen D1 Dopamine Receptor Supersensitivity in the Dopamine-Depleted Striatum , 2010 .

[544]  R. Moratalla,et al.  L-DOPA Treatment Selectively Restores Spine Density in Dopamine Receptor D2–Expressing Projection Neurons in Dyskinetic Mice , 2014, Biological Psychiatry.

[545]  G. Chiara,et al.  Priming of rotational behavior by a dopamine receptor agonist in hemiparkinsonian rats: Movement-dependent induction , 2009, Neuroscience.

[546]  G. Collingridge,et al.  Subcellular redistribution of the synapse‐associated proteins PSD‐95 and SAP97 in animal models of Parkinson&s disease and L‐DOPA‐induced dyskinesia , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[547]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[548]  S. Spieker,et al.  The NMDA antagonist budipine can alleviate levodopa‐induced motor fluctuations , 1999, Movement disorders : official journal of the Movement Disorder Society.

[549]  L. Tremblay,et al.  Tremor‐related activity of neurons in the ‘motor’ thalamus: changes in firing rate and pattern in the MPTP vervet model of parkinsonism , 2003, The European journal of neuroscience.

[550]  D. Black,et al.  A review of compulsive buying disorder. , 2007, World psychiatry : official journal of the World Psychiatric Association.

[551]  J. Brotchie,et al.  Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.

[552]  L. Tremblay,et al.  Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.

[553]  A. Björklund,et al.  L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA , 1998, The European journal of neuroscience.

[554]  J. Tesmer,et al.  A Surface of the Kinase Domain Critical for the Allosteric Activation of G Protein-coupled Receptor Kinases* , 2009, The Journal of Biological Chemistry.

[555]  C. Hammond,et al.  Dual Effect of High-Frequency Stimulation on Subthalamic Neuron Activity , 2003, The Journal of Neuroscience.

[556]  W. Danysz,et al.  Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease , 2007, Journal of neurochemistry.

[557]  L. Olson,et al.  Substantia nigra transplants into denervated striatum of the rat: Ultrastructure of graft and host interconnections , 1985, The Journal of comparative neurology.

[558]  Christos Tsironis,et al.  Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia. , 2012, European journal of pharmacology.

[559]  E I Canela,et al.  Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[560]  Y. Hurd,et al.  Coadministration of (−)-OSU6162 with l -DOPA Normalizes Preproenkephalin mRNA Expression in the Sensorimotor Striatum of Primates with Unilateral 6-OHDA Lesions , 2001, Experimental Neurology.

[561]  M. Olianas,et al.  Activation of nociceptin/orphanin FQ‐NOP receptor system inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and dopamine D1 receptor signaling in rat nucleus accumbens and dorsal striatum , 2008, Journal of neurochemistry.

[562]  T. Sotnikova,et al.  An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.

[563]  A. Mushegian,et al.  G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. , 2012, Pharmacology & therapeutics.

[564]  A. Björklund,et al.  mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats. , 2013, Journal of Parkinson's disease.

[565]  S. Mangiavacchi,et al.  D1 dopamine receptor stimulation increases the rate of AMPA receptor insertion onto the surface of cultured nucleus accumbens neurons through a pathway dependent on protein kinase A , 2004, Journal of neurochemistry.

[566]  P. Jenner Molecular mechanisms of L-DOPA-induced dyskinesia , 2008, Nature Reviews Neuroscience.

[567]  P. Singh,et al.  Molecular basis for activation of G protein‐coupled receptor kinases , 2010, The EMBO journal.

[568]  K. Fuxe,et al.  Stimulation of adenosine A2 receptors induces catalepsy , 1991, Neuroscience Letters.

[569]  Mark Hallett,et al.  Impulse control disorders in Parkinson's disease: recent advances. , 2011, Current opinion in neurology.

[570]  Antonio Oliviero,et al.  Oscillatory pallidal local field potential activity inversely correlates with limb dyskinesias in Parkinson's disease , 2005, Experimental Neurology.

[571]  L. Bard,et al.  Glutamate receptor dynamics and protein interaction: Lessons from the NMDA receptor , 2011, Molecular and Cellular Neuroscience.

[572]  T. Daigle,et al.  Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson’s disease , 2015, Proceedings of the National Academy of Sciences.

[573]  P. Redgrave,et al.  What is reinforced by phasic dopamine signals? , 2008, Brain Research Reviews.

[574]  L. Metman,et al.  A trial of dextromethorphan in parkinsonian patients with motor response complications , 1998, Movement disorders : official journal of the Movement Disorder Society.

[575]  Kwang-Soo Kim,et al.  Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. , 2003, Brain research. Molecular brain research.

[576]  E. Nestler,et al.  Elevated levels of ΔFosB and RGS9 in striatum in Parkinson’s disease , 2001, Biological Psychiatry.

[577]  J. Nutt,et al.  Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. , 2001, Archives of neurology.

[578]  M. Morari,et al.  Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia , 2015, Annals of clinical and translational neurology.

[579]  E. Bézard,et al.  Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys , 2004, Journal of Pharmacology and Experimental Therapeutics.

[580]  T. Chase,et al.  Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and l-DOPA administration , 1998, Brain Research.

[581]  A. Goodgold,et al.  Treatment failures with levodopa in parkinsonism , 1972, Neurology.

[582]  M. Cyr,et al.  Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat , 2010, Neurobiology of Disease.

[583]  E. Bézard,et al.  D1 Dopamine Receptor-Mediated LTP at GABA Synapses Encodes Motivation to Self-Administer Cocaine in Rats , 2013, The Journal of Neuroscience.

[584]  H. Lindgren,et al.  A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function , 2004, Neurobiology of Disease.

[585]  S. L. Kaplan A Self-Rated Scale for Obsessive-Compulsive Disorder. , 1994, Journal of clinical psychology.

[586]  C. Konradi,et al.  Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. , 2010, Progress in brain research.

[587]  S. Singer,et al.  The fluid mosaic model of the structure of cell membranes. , 1972, Science.

[588]  R. Moratalla,et al.  Activation of DREAM (Downstream Regulatory Element Antagonistic Modulator), a Calcium-Binding Protein, Reduces L-DOPA-Induced Dyskinesias in Mice , 2015, Biological Psychiatry.

[589]  E. Azmitia,et al.  An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat , 1978, The Journal of comparative neurology.

[590]  M. Smidt,et al.  Molecular mechanisms underlying midbrain dopamine neuron development and function. , 2003, European journal of pharmacology.

[591]  J. Brotchie,et al.  Effect of Repeated l -DOPA, Bromocriptine, or Lisuride Administration on Preproenkephalin-A and Preproenkephalin-B mRNA Levels in the Striatum of the 6-Hydroxydopamine-Lesioned Rat , 1999, Experimental Neurology.

[592]  S. Cragg,et al.  Nicotine amplifies reward-related dopamine signals in striatum , 2004, Nature Neuroscience.

[593]  J. Rothwell,et al.  Abnormal bidirectional plasticity-like effects in Parkinson's disease. , 2011, Brain : a journal of neurology.

[594]  L. Groc,et al.  Regulation of Dopamine D1 Receptor Dynamics within the Postsynaptic Density of Hippocampal Glutamate Synapses , 2013, PloS one.

[595]  E. Tronci,et al.  Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats , 2015, Behavioural Brain Research.

[596]  K. Steece-Collier,et al.  Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum. , 2012, Basal ganglia.

[597]  N. Quinn,et al.  L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates , 2007, Journal of neural transmission.

[598]  T. Chase,et al.  Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[599]  P. Calabresi,et al.  Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap , 2010, The Lancet Neurology.

[600]  K. Palczewski,et al.  Mechanism of rhodopsin kinase activation. , 1991, The Journal of biological chemistry.

[601]  M. Collu,et al.  Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease , 2014, Neuroscience.

[602]  R. Robertson,et al.  MPTP-Induced Parkinsonism in the Monkey: Neurochemical Pathology, Complications of Treatment and Pathophysiological Mechanisms , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[603]  M. Amalric,et al.  Cellular and Behavioral Outcomes of Dorsal Striatonigral Neuron Ablation: New Insights into Striatal Functions , 2014, Neuropsychopharmacology.

[604]  Gerfen Cr Dopamine-mediated gene regulation in models of Parkinson's disease. , 2000 .

[605]  C. Olanow,et al.  Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[606]  F. Turkheimer,et al.  Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease , 2011, Neurology.

[607]  J. Obeso,et al.  Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[608]  A. Serretti,et al.  Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. , 2014, The international journal of neuropsychopharmacology.

[609]  A. Rajput,et al.  Chronic low‐dose levodopa therapy in Parkinson's disease , 1984, Neurology.

[610]  T. Chase,et al.  A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease , 2003, Experimental Neurology.

[611]  D. D. Di Monte,et al.  Nicotine reduces levodopa‐induced dyskinesias in lesioned monkeys , 2007, Annals of neurology.

[612]  C. Capper-Loup,et al.  Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats , 2014, Front. Behav. Neurosci..

[613]  D. Hansel,et al.  Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. , 2005, Brain : a journal of neurology.

[614]  G. Bernardi,et al.  Lowered cAMP and cGMP signalling in the brain during levodopa‐induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms , 2008, The European journal of neuroscience.

[615]  W. Ko,et al.  Effects of l-tryptophan on l-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease , 2014, Neuroscience Letters.

[616]  L. Bour,et al.  Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial , 2013, The Lancet Neurology.

[617]  D. Lindenbach,et al.  Side effect profile of 5‐HT treatments for Parkinson's disease and L‐DOPA‐induced dyskinesia in rats , 2015, British journal of pharmacology.

[618]  M. Kathmann,et al.  Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors , 2002, British journal of pharmacology.

[619]  Grant D. Huang,et al.  Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. , 2010, The New England journal of medicine.

[620]  I. Mitchell,et al.  Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1987, Journal of the Neurological Sciences.

[621]  P. Greengard,et al.  Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines , 2006, European Neuropsychopharmacology.

[622]  Henrik Alm,et al.  Striatal Proteomic Analysis Suggests that First L-Dopa Dose Equates to Chronic Exposure , 2008, PloS one.

[623]  Y. Mizuno,et al.  Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[624]  S. Fasano,et al.  Ras–ERK Signaling in Behavior: Old Questions and New Perspectives , 2011, Front. Behav. Neurosci..

[625]  Daniela Berg,et al.  Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials , 2011 .

[626]  V. Sossi,et al.  Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. , 2006, Brain : a journal of neurology.

[627]  Hiroyuki Okuno,et al.  Regulation and function of immediate-early genes in the brain: Beyond neuronal activity markers , 2011, Neuroscience Research.

[628]  D. Calne,et al.  The long-term response to levodopa in dopa-responsive dystonia. , 2001, Parkinsonism & related disorders.

[629]  E. Bézard,et al.  Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease? , 2015, Brain : a journal of neurology.

[630]  Christian Hauptmann,et al.  Coordinated reset has sustained aftereffects in Parkinsonian monkeys , 2012, Annals of neurology.

[631]  J. Lanciego,et al.  l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus , 2014, Neuropharmacology.

[632]  Niall Quinn,et al.  Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.

[633]  Vesna Sossi,et al.  Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study , 2007, Annals of neurology.

[634]  E. Bézard,et al.  Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach , 1998, Progress in Neurobiology.

[635]  E. Tronci,et al.  Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations , 2014, Front. Neurol..

[636]  M. Quik,et al.  Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats , 2011, Neuropharmacology.

[637]  U. Gschwandtner,et al.  Pathologic gambling in patients with Parkinson's disease. , 2001, Clinical neuropharmacology.

[638]  High frequency stimulation of the subthalamic nucleus and levodopa induced dyskinesias in Parkinson's disease , 2000, Journal of neurology, neurosurgery, and psychiatry.

[639]  J. Benovic,et al.  Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. , 1996, Nature.

[640]  A. Björklund,et al.  Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia , 2013, Neuroscience Research.

[641]  O. Hornykiewicz,et al.  Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey , 1991, Neuroscience.

[642]  R. Arai,et al.  l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study , 1995, Neuroscience Letters.

[643]  Haruhiko Kishima,et al.  Functional Recovery in a Primate Model of Parkinson's Disease following Motor Cortex Stimulation , 2004, Neuron.

[644]  G. Meredith,et al.  The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors , 2008, Neurobiology of Disease.

[645]  M. Quik,et al.  Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[646]  J. Brotchie,et al.  Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia , 2004, Experimental Neurology.

[647]  J. C. Stoof,et al.  Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue. , 1997, European journal of pharmacology.

[648]  G. Fisone,et al.  Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease , 2013, Neuropharmacology.

[649]  M. Morelli,et al.  Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons , 2013, Experimental Neurology.

[650]  G. Fisone,et al.  L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission , 2011, Front. Behav. Neurosci..

[651]  D. Siderovski,et al.  The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits , 2005, International journal of biological sciences.

[652]  S. Iversen,et al.  Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. , 1990, Clinical neuropharmacology.

[653]  A. Deutch,et al.  Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism , 2005, The European journal of neuroscience.

[654]  E. Bézard,et al.  Compensatory Mechanisms in Experimental and Human Parkinsonism , 2009 .

[655]  P. Greengard,et al.  Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition , 2010, The Journal of Neuroscience.

[656]  C. Lindsley,et al.  Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist , 2015, Neuropharmacology.

[657]  L. Grégoire,et al.  The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. , 2011, Parkinsonism & related disorders.

[658]  M. Quik,et al.  Continuous and Intermittent Nicotine Treatment Reduces l-3,4-Dihydroxyphenylalanine (l-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[659]  J. Holden,et al.  6‐[18F]fluoro‐L‐DOPA PET studies of the turnover of dopamine in MPTP‐induced parkinsonism in monkeys , 1998, Synapse.

[660]  A. Sadikot,et al.  Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons , 2003, Development.

[661]  S. Grant,et al.  A role for the Ras signalling pathway in synaptic transmission and long-term memory , 1997, Nature.

[662]  M. Decker,et al.  ABT‐089 and ABT‐894 reduce levodopa‐induced dyskinesias in a monkey model of Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[663]  M. Marks,et al.  L-DOPA treatment modulates nicotinic receptors in monkey striatum. , 2003, Molecular pharmacology.

[664]  M. Morelli,et al.  Different responsiveness of striatonigral and striatopallidal neurons to L‐DOPA after a subchronic intermittent L‐DOPA treatment , 2005, The European journal of neuroscience.

[665]  J. Brotchie,et al.  L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. , 2015, Behavioural pharmacology.

[666]  E. Bézard,et al.  Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors , 2013, Proceedings of the National Academy of Sciences.

[667]  A. Björklund,et al.  Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia , 2013, Movement disorders : official journal of the Movement Disorder Society.

[668]  G. Kolata Monkey model of Parkinson's disease. , 1983, Science.

[669]  D. Riche,et al.  Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons , 1993, Neuroscience.

[670]  H. Bergman,et al.  Pathological synchronization in Parkinson's disease: networks, models and treatments , 2007, Trends in Neurosciences.

[671]  D J Brooks,et al.  Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias , 1997, Annals of neurology.

[672]  J. Brotchie,et al.  Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease , 2000, Experimental Neurology.

[673]  M. Matsunaga,et al.  Activation of 5‐HT1A but not 5‐HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered l‐DOPA in the striatum with nigrostriatal denervation , 2001, Journal of neurochemistry.

[674]  E. Bézard,et al.  Reinforcing properties of Pramipexole in normal and parkinsonian rats , 2013, Neurobiology of Disease.

[675]  J. Nyengaard,et al.  Endothelial Proliferation and Increased Blood–Brain Barrier Permeability in the Basal Ganglia in a Rat Model of 3,4-Dihydroxyphenyl-l-Alanine-Induced Dyskinesia , 2006, The Journal of Neuroscience.

[676]  P. Calabresi,et al.  Abnormal Ca2+-Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism , 2004, The Journal of Neuroscience.

[677]  S. Rosset,et al.  Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. , 2012, Parkinsonism & related disorders.

[678]  Ann M Graybiel,et al.  Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy , 2009, Proceedings of the National Academy of Sciences.

[679]  E. Bézard,et al.  Pattern of levodopa‐induced striatal changes is different in normal and MPTP‐lesioned mice , 2003, Journal of neurochemistry.

[680]  S. Fleming Cardiovascular autonomic dysfunction in animal models of Parkinson's disease. , 2011, Journal of Parkinson's disease.

[681]  G. Fisone,et al.  A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA–Induced Dyskinesia and ∆FosB Expression , 2016, Biological Psychiatry.

[682]  M. Cenci,et al.  l‐DOPA‐induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia , 2010, Journal of neurochemistry.

[683]  L. Savage,et al.  Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats , 2011, Experimental Neurology.

[684]  A. Triller,et al.  Fast and reversible trapping of surface glycine receptors by gephyrin , 2001, Nature Neuroscience.

[685]  M. Cenci,et al.  In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels , 2012, Neurobiology of Disease.

[686]  Qin Li,et al.  Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia , 2014, Neurobiology of Disease.

[687]  Joshua L. Plotkin,et al.  Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia , 2014, Nature Communications.

[688]  C. Waters,et al.  Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment , 1997, Neurology.

[689]  K. Fuxe,et al.  Identification of Dopamine D1–D3 Receptor Heteromers , 2008, Journal of Biological Chemistry.

[690]  R. Cantello Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies , 2000, Journal of neurology, neurosurgery, and psychiatry.

[691]  Stephen Tisch,et al.  The latest evidence on target selection in deep brain stimulation for Parkinson’s disease , 2014, Journal of Clinical Neuroscience.

[692]  S. Grady,et al.  Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice , 2012, Neuropharmacology.

[693]  C. Verney,et al.  G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[694]  J. Langston,et al.  Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa , 2005, Neuropharmacology.

[695]  P. Stanzione,et al.  Evidence of an association between sleep and levodopa-induced dyskinesia in an animal model of Parkinson's disease , 2015, Neurobiology of Aging.

[696]  E. Bézard,et al.  Dopamine Transporter Binding Is Unaffected by L-DOPA Administration in Normal and MPTP-Treated Monkeys , 2010, PloS one.

[697]  A. Nishi,et al.  PKA-Dependent Phosphorylation of Ribosomal Protein S6 Does Not Correlate with Translation Efficiency in Striatonigral and Striatopallidal Medium-Sized Spiny Neurons , 2015, Journal of Neuroscience.

[698]  O. Rascol,et al.  Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial , 2007, Movement disorders : official journal of the Movement Disorder Society.

[699]  G. Reynolds,et al.  [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. , 1985, European journal of pharmacology.

[700]  C. Mariani,et al.  Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[701]  I. Mitchell,et al.  Regional brain uptake of 2-deoxyglucose in N -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)—induced parkinsonism in the macaque monkey , 1985, Neuropharmacology.

[702]  C. V. van Duijn,et al.  Parkinson's disease: piecing together a genetic jigsaw. , 2003, Brain : a journal of neurology.

[703]  S. Grady,et al.  Nicotine Reduces l-DOPA-Induced Dyskinesias by Acting at β2* Nicotinic Receptors , 2011, Journal of Pharmacology and Experimental Therapeutics.

[704]  E. Nestler,et al.  Cloning and Characterization of RGS9-2: A Striatal-Enriched Alternatively Spliced Product of the RGS9 Gene , 1999, The Journal of Neuroscience.

[705]  L. Metman,et al.  Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease , 1998, Neurology.

[706]  W R Woodward,et al.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.

[707]  D. Grandy,et al.  Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor , 1995, Science.

[708]  E. Bézard,et al.  Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset , 2003, Movement disorders : official journal of the Movement Disorder Society.

[709]  Y. Geda,et al.  Pathological gambling caused by drugs used to treat Parkinson disease. , 2005, Archives of neurology.

[710]  W. Wetsel,et al.  Dopamine-Independent Locomotor Actions of Amphetamines in a Novel Acute Mouse Model of Parkinson Disease , 2005, PLoS biology.

[711]  W. Ko,et al.  RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease , 2014, Neurobiology of Disease.

[712]  B. Balleine,et al.  Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning , 2004, The European journal of neuroscience.

[713]  U Wilden,et al.  Duration and amplitude of the light-induced cGMP hydrolysis in vertebrate photoreceptors are regulated by multiple phosphorylation of rhodopsin and by arrestin binding. , 1995, Biochemistry.

[714]  J C Mazziotta,et al.  The lennox‐gastaut syndrome: Metabolic subtypes determined by 2‐deoxy‐2 [18F]fluoro‐d‐glucose positron emission tomography , 1987, Annals of neurology.

[715]  Britt Mellström,et al.  DREAM is a Ca2+-regulated transcriptional repressor , 1999, Nature.

[716]  W. Weiner,et al.  Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study) , 2012, Neurology.

[717]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[718]  Y. Michotte,et al.  MK801 suppresses the l-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats , 2002, Brain Research.

[719]  J. Dostrovsky,et al.  Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. , 2009, Brain : a journal of neurology.

[720]  Qin Li,et al.  Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. , 2015, Cerebral cortex.

[721]  S. Davis,et al.  Regulated transcription of the immediate‐early gene Zif268: Mechanisms and gene dosage‐dependent function in synaptic plasticity and memory formation , 2002, Hippocampus.

[722]  J. Jin,et al.  Inhibitory effect of capsaicin on the ascending pathway of the guinea-pig ileum and antagonism of this effect by ruthenium red. , 1990, European journal of pharmacology.

[723]  Paola Savoia,et al.  The tyrosine phosphatase Shp‐2 interacts with the dopamine D1 receptor and triggers D1‐mediated Erk signaling in striatal neurons , 2011, Journal of neurochemistry.

[724]  P. Salin,et al.  Chronic l‐DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease , 2004, The European journal of neuroscience.

[725]  Y. Agid,et al.  A multidisciplinary study of patients with early-onset PD with and without parkin mutations , 2009, Neurology.

[726]  P. Calabresi,et al.  Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[727]  J. Molgó,et al.  Ultrastructure of botulinum type-A poisoned frog motor nerve terminals after enhanced quantal transmitter release caused by carbonyl cyanide m-chlorophenylhydrazone , 1991, Neuroscience Letters.

[728]  H. Groenewegen,et al.  [Impulse control disorders in Parkinson's disease]. , 2011, Tijdschrift voor psychiatrie.

[729]  V. Voon,et al.  Medication-related impulse control and repetitive behaviors in Parkinson's disease , 2007, Current opinion in neurology.

[730]  Z. F. H. Cao,et al.  Dopamine‐dependent motor learning: Insight into levodopa's long‐duration response , 2009, Annals of neurology.

[731]  P. Pollak,et al.  Psychostimulant effect of levodopa: reversing sensitisation is possible , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[732]  Qin Li,et al.  Striatal Overexpression of ΔJunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson Disease , 2009, Biological Psychiatry.

[733]  V. Höllt Opioid peptide processing and receptor selectivity. , 1986, Annual review of pharmacology and toxicology.

[734]  M. Stacy,et al.  Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial , 2013, The Lancet Neurology.

[735]  W. Danysz,et al.  Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model , 2007, Behavioural Brain Research.

[736]  Fair M. Vassoler,et al.  Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. , 2011, Brain : a journal of neurology.

[737]  Charles Howard Adler,et al.  Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa , 1998 .

[738]  J. Brotchie,et al.  The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease , 2013, Pharmacological Reviews.

[739]  A. Korczyn,et al.  Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson’s Disease , 2014, Journal of Molecular Neuroscience.

[740]  G. Fisone,et al.  HDAC inhibitors conquer polycomb proteins , 2010 .

[741]  Vesna Sossi,et al.  Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.

[742]  C. Peretz,et al.  Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease , 2004, Journal of Neural Transmission.

[743]  E. Kultalahti,et al.  Twelve‐month safety of entacapone in patients with Parkinson’s disease , 2001, European journal of neurology.

[744]  A. Newman-Tancredi,et al.  Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia , 2015, Neuropharmacology.

[745]  A. Lawrence,et al.  Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward , 2010, Movement disorders : official journal of the Movement Disorder Society.

[746]  O. Rascol,et al.  A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease , 2012, Fundamental & clinical pharmacology.

[747]  Jungsu S. Oh,et al.  Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease , 2014, Neurology.

[748]  P. Gubellini,et al.  High-Frequency Stimulation of the Subthalamic Nucleus Potentiates l-DOPA-Induced Neurochemical Changes in the Striatum in a Rat Model of Parkinson's Disease , 2007, The Journal of Neuroscience.

[749]  Okihide Hikosaka,et al.  Habenula: Crossroad between the Basal Ganglia and the Limbic System , 2008, The Journal of Neuroscience.

[750]  P. Calabresi,et al.  Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease , 2012, The Journal of Neuroscience.

[751]  N. Wierup,et al.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease , 2002, The European journal of neuroscience.

[752]  Angus C Nairn,et al.  Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[753]  M. Morelli,et al.  Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions , 2004, Experimental Neurology.

[754]  J. Marinus,et al.  Catechol‐O‐methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[755]  T. Paolo,et al.  Modeling dyskinesia in animal models of Parkinson disease , 2014, Experimental Neurology.

[756]  Qin Li,et al.  The 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of l-DOPA-Induced Abnormal Involuntary Movements in Experimental Parkinson's Disease , 2008, The Journal of Neuroscience.

[757]  Ryan T. Strachan,et al.  Distinct Phosphorylation Sites on the β2-Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of β-Arrestin , 2011, Science Signaling.

[758]  A. Benazzouz,et al.  High-Frequency Stimulation of the Subthalamic Nucleus and l-3,4-Dihydroxyphenylalanine Inhibit In Vivo Serotonin Release in the Prefrontal Cortex and Hippocampus in a Rat Model of Parkinson's Disease , 2010, The Journal of Neuroscience.

[759]  R. Lefkowitz,et al.  Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. , 2011, Trends in biochemical sciences.

[760]  R. Roth,et al.  MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys , 1990, Brain Research.

[761]  Kuei Yuan Tseng,et al.  Nitric Oxide–Soluble Guanylyl Cyclase–Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease? , 2011, Front. Syst. Neurosci..

[762]  J. Brotchie,et al.  Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time , 2011, The Journal of Neuroscience.

[763]  G. Fisone,et al.  Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease. , 2011, Journal of Parkinson's disease.

[764]  S. Konitsiotis,et al.  Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.

[765]  J A Obeso,et al.  Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. , 2006, Brain : a journal of neurology.

[766]  H. Akil,et al.  Opioid receptor‐like (ORL1) receptor distribution in the rat central nervous system: Comparison of ORL1 receptor mRNA expression with 125I‐[14Tyr]‐orphanin FQ binding , 1999, The Journal of comparative neurology.

[767]  Cecilia Gotti,et al.  Diversity of vertebrate nicotinic acetylcholine receptors , 2009, Neuropharmacology.

[768]  J. Hwang,et al.  Inhibition of Adenylyl Cyclase Type 5 Prevents l-DOPA-Induced Dyskinesia in an Animal Model of Parkinson's Disease , 2014, The Journal of Neuroscience.

[769]  S. Kéri,et al.  Delay Discounting of Reward and Caudate Nucleus Volume in Individuals with α-Synuclein Gene Duplication before and after the Development of Parkinson’s Disease , 2012, Neurodegenerative Diseases.

[770]  Aaron DiAntonio,et al.  Ubiquitin-dependent regulation of the synapse. , 2004, Annual review of neuroscience.

[771]  F. Kolb,et al.  The human cerebellum contributes to motor, emotional and cognitive associative learning. A review , 2010, Cortex.

[772]  S. Kitamura,et al.  Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients , 2011, PloS one.

[773]  K. L. Leenders,et al.  Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers , 1988, Brain Research.

[774]  H. Akil,et al.  Nociceptin/orphanin FQ and opioid receptor‐like receptor mRNA expression in dopamine systems , 2002, The Journal of comparative neurology.

[775]  Kwang-Soo Kim,et al.  Dopaminergic neurons modulate GABA neuron migration in the embryonic midbrain , 2012, Development.

[776]  E. Bézard,et al.  Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys , 2001, Neurobiology of Disease.

[777]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[778]  Qin Li,et al.  PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. , 2012, The Journal of clinical investigation.

[779]  W. Schultz,et al.  Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism , 1985, Neuroscience Letters.

[780]  E. Bézard,et al.  Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia , 2011, Neuroscience.

[781]  C. Konradi,et al.  Spatiotemporal Pattern of Striatal ERK1/2 Phosphorylation in a Rat Model of L-DOPA–Induced Dyskinesia and the Role of Dopamine D1 Receptors , 2007, Biological Psychiatry.

[782]  N. Lambert,et al.  Rapid Activation of Inwardly Rectifying Potassium Channels by Immobile G-Protein-Coupled Receptors , 2006, The Journal of Neuroscience.

[783]  P. Greengard,et al.  Dichotomous Dopaminergic Control of Striatal Synaptic Plasticity , 2008, Science.

[784]  A. Crossman,et al.  Primate models of dyskinesia: The experimental approach to the study of basal ganglia-related involuntary movement disorders , 1987, Neuroscience.

[785]  Bryan L. Roth,et al.  Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.

[786]  A. Lang,et al.  Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. , 2000, The New England journal of medicine.

[787]  O. Rascol,et al.  Prevalence of orthostatic hypotension in Parkinson’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.

[788]  Robert J. Lefkowitz,et al.  Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands , 2009, Proceedings of the National Academy of Sciences.

[789]  Hagai Bergman,et al.  Dopamine Replacement Therapy Reverses Abnormal Synchronization of Pallidal Neurons in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Primate Model of Parkinsonism , 2002, The Journal of Neuroscience.

[790]  R P Lesser,et al.  Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy , 1979, Neurology.

[791]  M. Bortolanza,et al.  Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease , 2015, Neurobiology of Disease.

[792]  V. Francardo,et al.  Animal models of l-DOPA–induced dyskinesia: an update on the current options , 2012, Neuroscience.

[793]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[794]  K. Palczewski,et al.  Activation of G protein-coupled receptor kinase 1 involves interactions between its N-terminal region and its kinase domain. , 2011, Biochemistry.

[795]  G. Fisone,et al.  Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia , 2005, Experimental Neurology.

[796]  E. Bézard,et al.  Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia , 2014, Neurobiology of Disease.

[797]  Stanley Fahn,et al.  Dyskinesia after fetal cell transplantation for parkinsonism: A PET study , 2002, Annals of neurology.

[798]  S. Kish,et al.  Brain dopamine‐stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 2004, Annals of neurology.

[799]  R. Roth,et al.  Efferent synaptic connections of dopaminergic neurons grafted into the caudate nucleus of experimentally induced parkinsonian monkeys are different from those of control animals , 1998, Experimental Brain Research.

[800]  W. Poewe,et al.  Novel formulations and modes of delivery of levodopa , 2015, Movement disorders : official journal of the Movement Disorder Society.

[801]  M. Hallett,et al.  The cerebellum in Parkinson’s disease , 2013, Brain : a journal of neurology.

[802]  M. Cenci,et al.  Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease , 2012, Progress in Neurobiology.

[803]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[804]  Ian Q. Whishaw,et al.  Animal models of neurological deficits: how relevant is the rat? , 2002, Nature Reviews Neuroscience.

[805]  P. Greengard,et al.  Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l-DOPA–Induced Dyskinesia , 2009, Science Signaling.

[806]  W T Thach,et al.  The cerebellum and the adaptive coordination of movement. , 1992, Annual review of neuroscience.

[807]  A. D. Smith,et al.  Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy , 1984, Neuroscience.

[808]  G. Deuschl,et al.  Long‐term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation , 2011, Movement disorders : official journal of the Movement Disorder Society.

[809]  A. Gjedde,et al.  Serotonergic modulation of receptor occupancy in rats treated with l‐DOPA after unilateral 6‐OHDA lesioning , 2012, Journal of neurochemistry.

[810]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[811]  Karen L. Eskow Jaunarajs,et al.  Serotonin transporter inhibition attenuates l‐DOPA‐induced dyskinesia without compromising l‐DOPA efficacy in hemi‐parkinsonian rats , 2012, The European journal of neuroscience.

[812]  J. Jankovic,et al.  Treatment options for Parkinson's disease , 2002, Current opinion in neurology.

[813]  B Bioulac,et al.  Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[814]  Yen F. Tai,et al.  Clinical correlates of levodopa-induced dopamine release in Parkinson disease , 2006, Neurology.

[815]  B Bioulac,et al.  Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. , 2001, Brain : a journal of neurology.

[816]  A. Stoessl,et al.  Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa , 2003, Neuroscience.

[817]  S. Salvadori,et al.  Nociceptin/orphanin FQ receptor ligands , 2000, Peptides.

[818]  B. Sagot,et al.  Similar l-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation , 2015, Brain Research.

[819]  C. Konradi,et al.  Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia , 2004, Neurobiology of Disease.

[820]  A. Björklund,et al.  Role of serotonin neurons in the induction of levodopa‐ and graft‐induced dyskinesias in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[821]  N. Zaveri,et al.  Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP , 2005, The AAPS Journal.

[822]  Marc G Caron,et al.  Dopaminergic Supersensitivity in G Protein-Coupled Receptor Kinase 6-Deficient Mice , 2003, Neuron.

[823]  J. Bennett,et al.  Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long‐term dyskinesia reduction , 1994, Movement disorders : official journal of the Movement Disorder Society.

[824]  P. Jenner,et al.  Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? , 2006, Experimental Neurology.

[825]  E. Bézard,et al.  A tale on animal models of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[826]  Erwan Bezard,et al.  Astrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology? , 2014, Front. Aging Neurosci..

[827]  J. Brotchie,et al.  Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6‐OHDA lesioned marmoset , 1995, Behavioural pharmacology.

[828]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[829]  R. Hodgson,et al.  A2A receptor antagonists do not induce dyskinesias in drug-naive or l-dopa sensitized rats , 2013, Brain Research Bulletin.

[830]  James Parkinson,et al.  An essay on the shaking palsy. 1817. , 2002, The Journal of neuropsychiatry and clinical neurosciences.

[831]  Duncan P. Taylor Buspirone, a new approach to the treatment of anxiety , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[832]  Y. Agid,et al.  Effects of etybenzatropine and diazepam on levodopa‐induced diphasic dyskinesias in Parkinson's disease , 1989, Movement disorders : official journal of the Movement Disorder Society.

[833]  P. Lewitt,et al.  Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics , 2015, Movement disorders : official journal of the Movement Disorder Society.

[834]  R. Roth,et al.  Behavioral Effects of MPTP Administration in the Vervet Monkey , 1994 .

[835]  B. Fredholm,et al.  Deletion of adenosine A1 or A2A receptors reduces l-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease , 2011, Brain Research.

[836]  P. De Deurwaerdère,et al.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain. , 2013, ACS chemical neuroscience.

[837]  T. Napier,et al.  Pramipexole-Induced Increased Probabilistic Discounting: Comparison Between a Rodent Model of Parkinson's Disease and Controls , 2012, Neuropsychopharmacology.

[838]  S. Garattini,et al.  1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. , 1986, Pharmacology.

[839]  J. Kesslak,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease , 2001 .

[840]  H. Koh,et al.  The Roles of Striatal Serotonin and l-Amino-acid Decarboxylase on l-DOPA-induced Dyskinesia in a Hemiparkinsonian Rat Model , 2010, Cellular and Molecular Neurobiology.

[841]  Riccardo Viaro,et al.  The Nociceptin/Orphanin FQ Receptor Antagonist J-113397 and l-DOPA Additively Attenuate Experimental Parkinsonism through Overinhibition of the Nigrothalamic Pathway , 2007, The Journal of Neuroscience.

[842]  M. Sheng,et al.  PDZ domain proteins of synapses , 2004, Nature Reviews Neuroscience.

[843]  R. Watts,et al.  Striatal Overexpression of ΔFosB Reproduces Chronic Levodopa-Induced Involuntary Movements , 2010, The Journal of Neuroscience.

[844]  A. Nicholas Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine , 2007, Movement disorders : official journal of the Movement Disorder Society.

[845]  P. Jenner,et al.  Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity , 2005, Journal of Neural Transmission / General Section JNT.

[846]  J. Ahlskog,et al.  Levodopa‐dyskinesia incidence by age of Parkinson's disease onset , 2005, Movement disorders : official journal of the Movement Disorder Society.

[847]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[848]  J. Dostrovsky,et al.  Does stimulation of the GPi control dyskinesia by activating inhibitory axons? , 2001, Movement disorders : official journal of the Movement Disorder Society.

[849]  P. Greengard,et al.  Beyond the Dopamine Receptor: Review the DARPP-32/Protein Phosphatase-1 Cascade , 1999 .

[850]  Charles J. Wilson,et al.  RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion , 2006, Nature Neuroscience.

[851]  M. Quik,et al.  Nicotine as a potential neuroprotective agent for Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[852]  C. Barnum,et al.  The role of the dorsal raphe nucleus in the development, expression, and treatment of L‐dopa‐induced dyskinesia in hemiparkinsonian rats , 2009, Synapse.

[853]  D. Weinberger,et al.  BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[854]  W. Webb,et al.  Lateral motion of fluorescently labeled acetylcholine receptors in membranes of developing muscle fibers. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[855]  Anatol C. Kreitzer,et al.  Differential Innervation of Direct- and Indirect-Pathway Striatal Projection Neurons , 2013, Neuron.

[856]  Daniel Choquet,et al.  Differential activity-dependent regulation of the lateral mobilities of AMPA and NMDA receptors , 2004, Nature Neuroscience.

[857]  S. Snyder,et al.  Rhes, a striatal–enriched small G–protein, mediates mTOR signaling and L–DOPA–induced dyskinesia , 2011, Nature Neuroscience.

[858]  P. Calabresi,et al.  Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias , 2012, Neurobiology of Aging.

[859]  P. Svenningsson,et al.  Striatal Alterations of Secretogranin-1, Somatostatin, Prodynorphin, and Cholecystokinin Peptides in an Experimental Mouse Model of Parkinson Disease*S , 2009, Molecular & Cellular Proteomics.

[860]  A. Graybiel,et al.  Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis , 2000, Trends in Neurosciences.

[861]  J. Brotchie,et al.  TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque , 2013, Neuropharmacology.

[862]  J. Bloch,et al.  Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons , 2004, Neurobiology of Disease.

[863]  J. Yamada,et al.  Morphologic changes of dendritic spines of striatal neurons in the levodopa‐induced dyskinesia model , 2014, Movement disorders : official journal of the Movement Disorder Society.

[864]  Antonio Cerasa,et al.  Increased prefrontal volume in PD with levodopa‐induced dyskinesias: A voxel‐based morphometry study , 2011, Movement disorders : official journal of the Movement Disorder Society.

[865]  G. Di Chiara,et al.  "Priming" to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message. , 1993, Behavioural pharmacology.

[866]  J. Strachan,et al.  α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats , 2013, Neuropharmacology.

[867]  G. Fricchione,et al.  Opioid and opiate immunoregulatory processes. , 1996, Critical reviews in immunology.

[868]  R. Duvoisin,et al.  L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. , 1968, Transactions of the American Neurological Association.

[869]  A. Parent,et al.  Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia , 2010, Neurobiology of Disease.

[870]  S. Salvadori,et al.  Pharmacology of nociceptin and its receptor: a novel therapeutic target , 2000, British journal of pharmacology.

[871]  Guo-qiang Lu,et al.  Changes in Subcellular Distribution and Phosphorylation of GluR1 in Lesioned Striatum of 6-Hydroxydopamine-Lesioned and l-dopa-Treated Rats , 2006, Neurochemical Research.

[872]  M. Collu,et al.  5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model , 2013, Neurobiology of Disease.

[873]  J. Brotchie,et al.  Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson's Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.

[874]  J. Buccafusco,et al.  Desensitization of Nicotinic Acetylcholine Receptors as a Strategy for Drug Development , 2009, Journal of Pharmacology and Experimental Therapeutics.

[875]  P. Toro,et al.  Addiction to apomorphine: a clinical case-centred discussion. , 2006, Addiction.

[876]  Stephen S. G. Ferguson,et al.  Synergistic Regulation of β2-Adrenergic Receptor Sequestration: Intracellular Complement of β-Adrenergic Receptor Kinase and β-Arrestin Determine Kinetics of Internalization , 1997 .

[877]  S. Fereshtehnejad,et al.  Orthostatic Hypotension in Patients with Parkinson's Disease and Atypical Parkinsonism , 2014, Parkinson's disease.

[878]  A. Lees,et al.  Buspirone in the treatment of levodopa induced dyskinesias. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[879]  E. Sinforiani,et al.  Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease , 2006, Neurology.

[880]  Vsevolod V Gurevich,et al.  Regulation of Arrestin Binding by Rhodopsin Phosphorylation Level* , 2007, Journal of Biological Chemistry.

[881]  H. Sapru,et al.  Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors , 2014, Behavioural Brain Research.

[882]  A. Beckmann,et al.  Egr transcription factors in the nervous system , 1997, Neurochemistry International.

[883]  Alcino J. Silva,et al.  The HMG-CoA Reductase Inhibitor Lovastatin Reverses the Learning and Attention Deficits in a Mouse Model of Neurofibromatosis Type 1 , 2005, Current Biology.

[884]  R. Huganir,et al.  The cell biology of synaptic plasticity: AMPA receptor trafficking. , 2007, Annual review of cell and developmental biology.

[885]  David Garcia-Garcia,et al.  Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. , 2011, Brain : a journal of neurology.

[886]  W. Sadee,et al.  Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. , 2005, Life sciences.

[887]  M. Quik,et al.  The nicotine‐mediated decline in l‐dopa‐induced dyskinesias is associated with a decrease in striatal dopamine release , 2013, Journal of neurochemistry.

[888]  P. Calabresi,et al.  Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. , 2011, Brain : a journal of neurology.

[889]  H. Heinze,et al.  Ageing and early-stage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing. , 2007, Brain : a journal of neurology.

[890]  V Sossi,et al.  A Reversible Tracer Analysis Approach to the Study of Effective Dopamine Turnover , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[891]  C. Marsden,et al.  Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of parkinson's disease patients , 1994, Neuroscience.

[892]  L. Lopiano,et al.  Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[893]  N. Quinn Classification of fluctuations in patients with Parkinson's disease , 1998, Neurology.

[894]  J. Cianfrogna,et al.  Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. , 2014, Journal of medicinal chemistry.

[895]  Zhenguo Liu,et al.  Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats , 2014, Scientific Reports.

[896]  A. Newman,et al.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.

[897]  B. Averbeck,et al.  Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[898]  P. Sokoloff,et al.  Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[899]  L. Tremblay,et al.  Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP‐treated monkeys , 2003, The European journal of neuroscience.

[900]  B. Bioulac,et al.  A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France , 2007, Movement disorders : official journal of the Movement Disorder Society.

[901]  Erwan Bezard,et al.  Enhanced Preproenkephalin-B–Derived Opioid Transmission in Striatum and Subthalamic Nucleus Converges Upon Globus Pallidus Internalis in L-3,4-dihydroxyphenylalanine–Induced Dyskinesia , 2007, Biological Psychiatry.

[902]  C. Gerfen,et al.  Priming for l-dopa-induced dyskinesia in Parkinson’s disease: A feature inherent to the treatment or the disease? , 2009, Progress in Neurobiology.

[903]  S B Dunnett,et al.  Behavioural analysis of unilateral monoamine depletion in the marmoset. , 1992, Brain : a journal of neurology.

[904]  Robert E. Burke,et al.  Pitx3 is required for development of substantia nigra dopaminergic neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[905]  J. Volkmann DEEP BRAIN STIMULATION II Deep Brain Stimulation for the Treatment of Parkinson’s Disease , 2004 .

[906]  E. Bézard,et al.  Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats , 2008, Neuroscience.

[907]  E. Nestler,et al.  Regulators of G-Protein Signaling (RGS) Proteins: Region-Specific Expression of Nine Subtypes in Rat Brain , 1997, The Journal of Neuroscience.

[908]  P. Calabresi,et al.  Targeting striatal cholinergic interneurons in Parkinson’s disease: Focus on metabotropic glutamate receptors , 2003, Neuropharmacology.

[909]  A. Benabid,et al.  Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 2003, The New England journal of medicine.

[910]  M. Mcdermott,et al.  Risk factors for somnolence, edema, and hallucinations in early Parkinson disease , 2007, Neurology.

[911]  Kwang-Soo Kim,et al.  Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson’s disease , 2007, Neurobiology of Disease.

[912]  W. Danysz,et al.  Pharmacological Modulation of Glutamate Transmission in a Rat Model of l-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling , 2009, Journal of Pharmacology and Experimental Therapeutics.

[913]  G. Chiara,et al.  Increased striatal expression of glutamate decarboxylase 67 after priming of 6-hydroxydopamine-lesioned rats , 1999, Neuroscience.

[914]  A. Triller,et al.  The Dynamic Synapse , 2013, Neuron.

[915]  J. Girault,et al.  Persistent Increase in Olfactory Type G-Protein α Subunit Levels May Underlie D1 Receptor Functional Hypersensitivity in Parkinson Disease , 2004, The Journal of Neuroscience.

[916]  Tommaso Pizzorusso,et al.  Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) Controls Activation of Extracellular Signal-Regulated Kinase (ERK) Signaling in the Striatum and Long-Term Behavioral Responses to Cocaine , 2009, Biological Psychiatry.

[917]  J. Brotchie,et al.  UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset , 2014, Neuropharmacology.

[918]  J. Villemure,et al.  Absence of cholinergic deficits in “pure” vascular dementia , 2005, Neurology.

[919]  Y Tateno,et al.  Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[920]  C. Gerfen,et al.  Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[921]  Adam T. Brewer,et al.  Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats , 2010, Psychopharmacology.

[922]  P. Calabresi,et al.  Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia , 2011, Experimental Neurology.

[923]  B. MacVicar,et al.  D1 Receptors Physically Interact with N-Type Calcium Channels to Regulate Channel Distribution and Dendritic Calcium Entry , 2008, Neuron.

[924]  K. Steece-Collier,et al.  Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats , 2010, The European journal of neuroscience.

[925]  W. Link,et al.  DREAM-αCREM Interaction via Leucine-Charged Domains Derepresses Downstream Regulatory Element-Dependent Transcription , 2000, Molecular and Cellular Biology.

[926]  Robert Savit,et al.  Seizure prediction using scalp electroencephalogram , 2003, Experimental Neurology.

[927]  K. Richard Ridderinkhof,et al.  The Effect of Parkinson's Disease on the Dynamics of On-line and Proactive Cognitive Control during Action Selection , 2010, Journal of Cognitive Neuroscience.

[928]  J. Joyce,et al.  Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis , 1989, Brain Research.

[929]  M. Merello,et al.  Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. , 1999, Clinical neuropharmacology.

[930]  J. Sassin,et al.  Hyperkinesia and changes in behavior produced in normal monkeys by L‐dopa , 1972, Neurology.

[931]  Qin Li,et al.  The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model , 2014, Movement disorders : official journal of the Movement Disorder Society.

[932]  M. Emborg,et al.  Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without l-DOPA administration , 2005, Neurobiology of Disease.

[933]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[934]  Jeffrey S. Stein,et al.  Effects of acute pramipexole on male rats' preference for gambling-like rewards II. , 2012, Experimental and clinical psychopharmacology.

[935]  Philippe Rostaing,et al.  Diffusion Dynamics of Glycine Receptors Revealed by Single-Quantum Dot Tracking , 2003, Science.

[936]  P. Calabresi,et al.  L‐3,4‐dihydroxyphenylalanine‐induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias? , 2010, Annals of neurology.

[937]  J. Penney,et al.  Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial , 2002, Annals of neurology.

[938]  M. Quik,et al.  Nicotinic Receptor-Mediated Reduction in l-DOPA-Induced Dyskinesias May Occur via Desensitization , 2010, Journal of Pharmacology and Experimental Therapeutics.

[939]  P. Calabresi,et al.  Targeting metabotropic glutamate receptors as a new strategy against levodopa‐induced dyskinesia in Parkinson's disease? , 2014, Movement disorders : official journal of the Movement Disorder Society.

[940]  T. Daigle,et al.  A Dopamine D1 Receptor-Dependent β-Arrestin Signaling Complex Potentially Regulates Morphine-Induced Psychomotor Activation but not Reward in Mice , 2011, Neuropsychopharmacology.

[941]  Vesna Sossi,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover , 2001 .

[942]  K. Lyons,et al.  Efficacy and Tolerability of Levetiracetam in Parkinson Disease Patients With Levodopa-Induced Dyskinesia , 2006, Clinical neuropharmacology.

[943]  J. Tesmer,et al.  Recognition in the Face of Diversity: Interactions of Heterotrimeric G proteins and G Protein-coupled Receptor (GPCR) Kinases with Activated GPCRs* , 2011, The Journal of Biological Chemistry.

[944]  Jie Zhang,et al.  The β2-adrenergic receptor/βarrestin complex recruits the clathrin adaptor AP-2 during endocytosis , 1999 .

[945]  D. D. Di Monte,et al.  Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model , 2000, Movement disorders : official journal of the Movement Disorder Society.

[946]  M. Cenci,et al.  Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease , 2011, Neurobiology of Disease.

[947]  Y. Goshima,et al.  Evidence for l-DOPA systems responsible for cardiovascular control in the nucleus tractus solitarii of the rat , 1992, Neuroscience Letters.

[948]  M. Quik,et al.  Differential nicotinic receptor expression in monkey basal ganglia: Effects of nigrostriatal damage , 2002, Neuroscience.

[949]  Necmettin Yildirim,et al.  β2-Adrenergic Receptor Signaling and Desensitization Elucidated by Quantitative Modeling of Real Time cAMP Dynamics* , 2008, Journal of Biological Chemistry.

[950]  G. Chiara,et al.  Stereospecific blockade of N-methyl-d-aspartate transmission by MK 801 prevents priming of SKF 38393-induced turning , 2005, Psychopharmacology.

[951]  Y. Agid,et al.  Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[952]  R. Duvoisin Cholinergic-anticholinergic antagonism in parkinsonism. , 1967, Archives of neurology.

[953]  J. Mink THE BASAL GANGLIA: FOCUSED SELECTION AND INHIBITION OF COMPETING MOTOR PROGRAMS , 1996, Progress in Neurobiology.

[954]  Aaron C. Katzman,et al.  Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats , 2014, Neuropharmacology.

[955]  R. P. Maguire,et al.  Pharmacological and PET studies in patient’s with Parkinson’s disease and a short duration-motor response: implications in the pathophysiology of motor complications , 2004, Journal of Neural Transmission.

[956]  S. Haber,et al.  Closed-Loop Deep Brain Stimulation Is Superior in Ameliorating Parkinsonism , 2011, Neuron.

[957]  N. Mons,et al.  Selective expression of one Ca(2+)-inhibitable adenylyl cyclase in dopaminergically innervated rat brain regions. , 1994, Brain research. Molecular brain research.

[958]  E. Nestler,et al.  ΔFosB Induction in Striatal Medium Spiny Neuron Subtypes in Response to Chronic Pharmacological, Emotional, and Optogenetic Stimuli , 2013, Journal of Neuroscience.

[959]  Gilberto Fisone,et al.  Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia , 2005, Annals of neurology.

[960]  W. Tourtellotte,et al.  The Neuroplasticity-Associated Arc Gene Is a Direct Transcriptional Target of Early Growth Response (Egr) Transcription Factors , 2005, Molecular and Cellular Biology.

[961]  Erin M. Schuman,et al.  Activity-dependent dynamics and sequestration of proteasomes in dendritic spines , 2006, Nature.

[962]  M. Caron,et al.  Differential Regulation of the Dopamine D2and D3 Receptors by G Protein-coupled Receptor Kinases and β-Arrestins* , 2001, The Journal of Biological Chemistry.

[963]  P. Jenner,et al.  Antiparkinsonian activity and dyskinesia risk of ropinirole and L‐DOPA combination therapy in drug naive MPTP‐lesioned common marmosets (Callithrix jacchus) , 2001, Movement disorders : official journal of the Movement Disorder Society.

[964]  K. Dalby,et al.  Dopamine depletion and subsequent treatment with l‐DOPA, but not the long‐lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum , 2007, Journal of neurochemistry.

[965]  C. Benkelfat,et al.  The Dopamine Augmenter L-DOPA Does Not Affect Positive Mood in Healthy Human Volunteers , 2012, PloS one.

[966]  S. Salvadori,et al.  Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. , 1997, Journal of medicinal chemistry.

[967]  U. Dillmann,et al.  Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. , 2014, Parkinsonism & related disorders.

[968]  M. Angela Cenci,et al.  cAMP Response Element-Binding Protein Is Required for Dopamine-Dependent Gene Expression in the Intact But Not the Dopamine-Denervated Striatum , 2001, The Journal of Neuroscience.

[969]  Erwan Bezard,et al.  Levodopa‐induced dyskinesia in MPTP‐treated macaques is not dependent on the extent and pattern of nigrostrial lesioning , 2005, The European journal of neuroscience.

[970]  J. Benovic,et al.  Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder , 2011, Neurobiology of Disease.

[971]  C. Perry Clinical Features , 2004, Bristol medico-chirurgical journal.

[972]  David Eidelberg,et al.  Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease , 2008, The Journal of Neuroscience.

[973]  D. Murphy,et al.  L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients. , 1970, Biological psychiatry.

[974]  D. Nyholm,et al.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.

[975]  Philippe Hantraye,et al.  Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia , 2009, Science Translational Medicine.

[976]  E. Schuman,et al.  Ubiquitin-Mediated Proteasome Activity Is Required for Agonist-Induced Endocytosis of GluRs , 2003, Current Biology.

[977]  R. Gainetdinov,et al.  The Akt-GSK-3 signaling cascade in the actions of dopamine. , 2007, Trends in pharmacological sciences.

[978]  Maurizio Massi,et al.  UFP‐112 a Potent and Long‐Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor , 2011, CNS neuroscience & therapeutics.

[979]  Mikhail N. Koffarnus,et al.  Effects of selective dopaminergic compounds on a delay-discounting task , 2011, Behavioural pharmacology.

[980]  Bettina Schrader,et al.  Two‐year follow‐up of subthalamic deep brain stimulation in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[981]  J A Obeso,et al.  Preventing levodopa-induced dyskinesias. , 2000, Annals of neurology.

[982]  J. Brotchie,et al.  L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2012, Journal of Pharmacology and Experimental Therapeutics.

[983]  M. Cenci,et al.  Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesia , 2003, Journal of neurochemistry.

[984]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[985]  K. Burchiel,et al.  Randomized trial of deep brain stimulation for Parkinson disease , 2012, Neurology.

[986]  James Robert Brašić,et al.  VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease , 2008, Journal of neurochemistry.

[987]  R. Nicoll,et al.  Diversity in NMDA Receptor Composition , 2013, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[988]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[989]  R. Hauser,et al.  Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[990]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[991]  A. Björklund,et al.  Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study , 2015, Brain : a journal of neurology.

[992]  T. Chase,et al.  Glutamate release inhibition ineffective in Levodopa‐induced motor complications , 2006, Movement disorders : official journal of the Movement Disorder Society.

[993]  Andreas R. Luft,et al.  Dopaminergic Meso-Cortical Projections to M1: Role in Motor Learning and Motor Cortex Plasticity , 2013, Front. Neurol..

[994]  G. Brighetti,et al.  Prevalence of pathological gambling in patients with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[995]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[996]  Werner Poewe,et al.  Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.

[997]  Jorge Iriarte,et al.  Coupling between Beta and High-Frequency Activity in the Human Subthalamic Nucleus May Be a Pathophysiological Mechanism in Parkinson's Disease , 2010, The Journal of Neuroscience.

[998]  Micaela Morelli,et al.  Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease , 2007, Synapse.

[999]  Paolo Calabresi,et al.  Dopamine-mediated regulation of corticostriatal synaptic plasticity , 2007, Trends in Neurosciences.

[1000]  Charles J. Wilson,et al.  Spontaneous Activity of Neostriatal Cholinergic Interneurons In Vitro , 1999, The Journal of Neuroscience.

[1001]  P. Llorca,et al.  Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and l-dopa, in bilateral 6-OHDA-lesioned rat , 2013, Neuropharmacology.

[1002]  S. Varanese,et al.  NMDA antagonist memantine improves levodopa‐induced dyskinesias and “On‐off” phenomena in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[1003]  V. Voon,et al.  Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[1004]  M. Palkovits,et al.  Distribution of nociceptin/orphanin FQ in adult human brain , 2004, Brain Research.

[1005]  A. Lawrence,et al.  Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease , 2005, Neurology.

[1006]  A. Dagher,et al.  Amphetamine-Induced Increases in Extracellular Dopamine, Drug Wanting, and Novelty Seeking: A PET/[11C]Raclopride Study in Healthy Men , 2002, Neuropsychopharmacology.

[1007]  L. Grégoire,et al.  mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys , 2008, Neurobiology of Aging.

[1008]  P. Worley,et al.  Immediate-Early Genes and Synaptic Function , 1998, Neurobiology of Learning and Memory.

[1009]  Micaela Morelli,et al.  Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions , 1994, Trends in Neurosciences.

[1010]  E M Ross,et al.  GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. , 2000, Annual review of biochemistry.

[1011]  P. Brundin,et al.  The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat , 2006, Neurobiology of Disease.

[1012]  G. Chiara,et al.  Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: Changes in DARPP-32 phosphorylation , 1994, Neuroscience.

[1013]  R. Palmiter,et al.  Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[1014]  B. Bioulac,et al.  Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease , 2010, Neurobiology of Disease.

[1015]  A. Björklund,et al.  Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons , 2012, Neurobiology of Disease.

[1016]  E. Storey,et al.  Influence of Single Nucleotide Polymorphisms in COMT, MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease , 2013, Neurodegenerative Diseases.

[1017]  MK‐801 alters the effects of priming with L‐DOPA on dopamine D1 receptor‐induced changes in neuropeptide mRNA levels in the rat striatal output neurons , 2002, Synapse.

[1018]  A. Sampson,et al.  Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models , 2006, Nature Neuroscience.

[1019]  S. Sarubbo,et al.  Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinson's Disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[1020]  L. Rumbach,et al.  Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of l-dopa therapy , 2004, Autonomic Neuroscience.

[1021]  F. Zhou,et al.  Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice , 2013, Neuroscience.

[1022]  Johannes Schwarz,et al.  D2 Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways , 2005, The Journal of Neuroscience.

[1023]  P. Ballard,et al.  Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[1024]  Regina Katzenschlager,et al.  Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome , 2004, Movement disorders : official journal of the Movement Disorder Society.

[1025]  A. Gobert,et al.  α2‐Adrenergic Receptor Blockade Markedly Potentiates Duloxetine‐ and Fluoxetine‐Induced Increases in Noradrenaline, Dopamine, and Serotonin Levels in the Frontal Cortex of Freely Moving Rats , 1997 .

[1026]  R. Barker,et al.  Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial , 2014, The Lancet.

[1027]  E. Hirsch,et al.  Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication , 2009, Journal of neurochemistry.

[1028]  M. Hutz,et al.  DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. , 2012, Pharmacogenomics.

[1029]  G F Koob,et al.  Drug abuse: hedonic homeostatic dysregulation. , 1997, Science.

[1030]  H. Bengtsson,et al.  Serotonin autoreceptor function and antidepressant drug action , 2000, Journal of psychopharmacology.

[1031]  R. Hauser,et al.  Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[1032]  P. De Deurwaerdère,et al.  Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia , 2011, Parkinson's disease.

[1033]  Antoine Triller,et al.  Synaptic stability and plasticity in a floating world , 2010, Current Opinion in Neurobiology.

[1034]  O. Rascol,et al.  Clozapine improves dyskinesias in Parkinson disease , 2004, Neurology.

[1035]  E. Nestler,et al.  Induction of Activating Transcription Factors (ATFs) ATF2, ATF3, and ATF4 in the Nucleus Accumbens and Their Regulation of Emotional Behavior , 2008, The Journal of Neuroscience.

[1036]  A. Giuditta,et al.  Protein-synthesizing machinery in the axon compartment , 1999, Neuroscience.

[1037]  D. Mash,et al.  Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson's disease , 2001 .

[1038]  E. Bézard,et al.  Pharmacological Analysis Demonstrates Dramatic Alteration of D1 Dopamine Receptor Neuronal Distribution in the Rat Analog of l-DOPA-Induced Dyskinesia , 2009, The Journal of Neuroscience.

[1039]  J. Langston,et al.  Investigating levodopa-induced dyskinesias in the parkinsonian primate. , 2000, Annals of neurology.

[1040]  K. Dalby,et al.  Overexpression of GRK6 rescues l-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats , 2015, Experimental Neurology.

[1041]  C. Tanner,et al.  Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) , 2015, Movement disorders : official journal of the Movement Disorder Society.

[1042]  M. Rizzone,et al.  80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: effects on involuntary movements. , 2013, Parkinsonism & related disorders.

[1043]  A. Björklund,et al.  Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model , 2009, Experimental Neurology.

[1044]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[1045]  P. Greengard,et al.  l‐DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice , 2009, Journal of neurochemistry.

[1046]  Andreea C. Bostan,et al.  The basal ganglia communicate with the cerebellum , 2010, Proceedings of the National Academy of Sciences.

[1047]  T. Roth,et al.  Sleepiness in Parkinson's disease: A controlled study , 2003, Movement disorders : official journal of the Movement Disorder Society.

[1048]  W. Danysz,et al.  Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease , 2006, Brain Research Bulletin.

[1049]  M. Onofrj,et al.  Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. , 2004, Journal of neurology, neurosurgery, and psychiatry.

[1050]  E. Bézard,et al.  Molecular mechanisms of l-DOPA-induced dyskinesia. , 2011, International review of neurobiology.

[1051]  P. Ravenscroft,et al.  Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease , 2010, Journal of neurochemistry.

[1052]  P. Spano,et al.  Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.

[1053]  W. Koch,et al.  Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. , 1998, American journal of physiology. Heart and circulatory physiology.

[1054]  D. Riche,et al.  Riluzole Reduces Incidence of Abnormal Movements but Not Striatal Cell Death in a Primate Model of Progressive Striatal Degeneration , 1997, Experimental Neurology.

[1055]  B Bioulac,et al.  Reversal of Rigidity and Improvement in Motor Performance by Subthalamic High‐frequency Stimulation in MPTP‐treated Monkeys , 1993, The European journal of neuroscience.

[1056]  R. Roth,et al.  Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus) , 1997, Neuroscience.

[1057]  Qin Li,et al.  Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA–Induced Dyskinesia , 2016, Biological Psychiatry.

[1058]  D. Choquet,et al.  Regulation of AMPA receptor lateral movements , 2002, Nature.

[1059]  Qin Li,et al.  l-DOPA Impairs Proteasome Activity in Parkinsonism through D1 Dopamine Receptor , 2012, The Journal of Neuroscience.

[1060]  Jee-Young Lee,et al.  Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[1061]  S. Liggett,et al.  Phosphorylation Barcoding as a Mechanism of Directing GPCR Signaling , 2011, Science Signaling.

[1062]  R. Veh,et al.  Individual neurons in the rat lateral habenular complex project mostly to the dopaminergic ventral tegmental area or to the serotonergic raphe nuclei , 2012, The Journal of comparative neurology.

[1063]  P. Greengard,et al.  Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism* , 2012, The Journal of Biological Chemistry.

[1064]  Y. Agid,et al.  Low-dose clozapine improves dyskinesias in Parkinson's disease , 1997, Neurology.

[1065]  J. Kordower,et al.  Primate models of Parkinson’s disease , 2003, Experimental Neurology.

[1066]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[1067]  R. Palmiter,et al.  Restoration of dopamine signaling to the dorsal striatum is sufficient for aspects of active maternal behavior in female mice. , 2013, Endocrinology.

[1068]  E. López‐Valdés,et al.  Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[1069]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[1070]  V. Sossi,et al.  Increase in Dopamine Turnover Occurs Early in Parkinson's Disease: Evidence from a New Modeling Approach to PET 18F-Fluorodopa Data , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[1071]  B Anton,et al.  Immunohistochemical localization of ORL‐1 in the central nervous system of the rat , 1996, The Journal of comparative neurology.

[1072]  J. Surmeier,et al.  Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models , 2014, Neurobiology of Disease.

[1073]  A. Björklund,et al.  Involvement of the serotonin system in L-dopa-induced dyskinesias. , 2008, Parkinsonism & related disorders.

[1074]  Qin Li,et al.  L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum , 2014, Scientific Reports.

[1075]  J. Deniau,et al.  Synaptic Convergence of Motor and Somatosensory Cortical Afferents onto GABAergic Interneurons in the Rat Striatum , 2002, Journal of Neuroscience.

[1076]  J. Nutt,et al.  Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.

[1077]  Anders Björklund,et al.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.

[1078]  C. Waters,et al.  Compulsive eating and weight gain related to dopamine agonist use , 2006, Movement disorders : official journal of the Movement Disorder Society.

[1079]  R. Lefkowitz,et al.  Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[1080]  L. Verhagen Metman,et al.  Internal pallidal neuronal activity during mild drug-related dyskinesias in Parkinson's disease: decreased firing rates and altered firing patterns. , 2007, Journal of neurophysiology.

[1081]  S. Grant,et al.  Inhibition of the Dopamine D1 Receptor Signaling by PSD-95*♦ , 2007, Journal of Biological Chemistry.

[1082]  S. Watson,et al.  Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat , 1999, The Journal of comparative neurology.

[1083]  B. Balleine,et al.  The role of the dorsomedial striatum in instrumental conditioning , 2005, The European journal of neuroscience.

[1084]  Qin Li,et al.  A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys , 2010, Neurobiology of Disease.

[1085]  M. Savasta,et al.  Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission , 1988, Neuroscience Letters.

[1086]  A. Björklund,et al.  Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease , 2012, Neurobiology of Disease.

[1087]  V. Sossi,et al.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.

[1088]  J. Brotchie,et al.  Non‐subtype‐selective opioid receptor antagonism in treatment of levodopa‐induced motor complications in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[1089]  R. Tsien,et al.  The Fluorescent Toolbox for Assessing Protein Location and Function , 2006, Science.

[1090]  J. Changeux Allosteric receptors: from electric organ to cognition. , 2010, Annual review of pharmacology and toxicology.

[1091]  L. Grégoire,et al.  Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys , 2004, Neurobiology of Disease.

[1092]  Marc G Caron,et al.  DDD mice, a novel acute mouse model of Parkinson’s disease , 2006, Neurology.

[1093]  O. Blin,et al.  Levodopa-induced Drowsiness in Healthy Volunteers: Results of a Choice Reaction Time Test Combined with a Subjective Evaluation of Sedation , 2001, Clinical neuropharmacology.

[1094]  L. Defebvre,et al.  Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson’s disease: a second honeymoon , 2009, Journal of Neurology.

[1095]  P. Calabresi,et al.  Nociceptin/Orphanin FQ Receptor Agonists Attenuate l-DOPA-Induced Dyskinesias , 2012, The Journal of Neuroscience.

[1096]  J D Corbit,et al.  An opponent-process theory of motivation. II. Cigarette addiction. , 1973, Journal of abnormal psychology.

[1097]  Johannes Schwarz,et al.  RGS9 Modulates Dopamine Signaling in the Basal Ganglia , 2003, Neuron.

[1098]  O. Rascol,et al.  Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. , 2014, Parkinsonism & related disorders.

[1099]  R Barber,et al.  Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution. , 1996, Molecular pharmacology.

[1100]  H. Steinbusch,et al.  Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus , 2007, Proceedings of the National Academy of Sciences.

[1101]  K. Elisabet Ohlin,et al.  Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease , 2012, NeuroImage.

[1102]  E. Bézard,et al.  High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey , 1996, Neuroscience Letters.

[1103]  J. Jankovic,et al.  Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. , 2014, Parkinsonism & related disorders.

[1104]  G. Fisone,et al.  Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons , 2007, Neuroscience & Biobehavioral Reviews.

[1105]  J. Obeso,et al.  Successful thalamic deep brain stimulation for orthostatic tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[1106]  S. Konitsiotis,et al.  AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys , 2000, Neurology.

[1107]  J. McGinty,et al.  RGS4 overexpression in the rat dorsal striatum modulates mGluR5- and amphetamine-mediated behavior and signaling , 2011, Psychopharmacology.

[1108]  C. N. Homann,et al.  Experience, competency, and education: Graduating neurology residents’ experience with tPA , 2001, Neurology.

[1109]  A. Björklund,et al.  The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation , 2014, Neurobiology of Disease.

[1110]  M. Okun,et al.  Unilateral GPi-DBS as a Treatment for Levodopa-Induced Respiratory Dyskinesia in Parkinson Disease , 2011, The neurologist.

[1111]  J. Maloteaux,et al.  Opposite modulation of regulators of G protein signalling-2 (RGS2) and RGS4 expression by dopamine receptors in the rat striatum , 2002, Neuroscience Letters.

[1112]  E. Bézard,et al.  Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. , 2013, Parkinsonism & related disorders.

[1113]  A. Nambu Seven problems on the basal ganglia , 2008, Current Opinion in Neurobiology.

[1114]  S. Grady,et al.  Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. , 2013, Biochemical pharmacology.

[1115]  M. Bencherif,et al.  Nicotinic Receptor Agonists Reduce l-DOPA–Induced Dyskinesias in a Monkey Model of Parkinson's Disease , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[1116]  Marc G Caron,et al.  Desensitization of G protein-coupled receptors and neuronal functions. , 2004, Annual review of neuroscience.

[1117]  A. Lang,et al.  The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[1118]  M. Geffard,et al.  The metabolism of exogenous L-Dopa in the brain: An immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain , 1991, Journal of neural transmission. Parkinson's disease and dementia section.

[1119]  Henrik Alm,et al.  Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: A proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE , 2006, BMC Bioinformatics.

[1120]  G. Fisone,et al.  mTORC1 signaling in Parkinson disease and L-DOPA-induced dyskinesia: A sensitized matter , 2010, Cell cycle.

[1121]  G. Robertson,et al.  D1-Receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression. , 1998, Brain research. Molecular brain research.

[1122]  Rui M. Costa,et al.  Rapid Alterations in Corticostriatal Ensemble Coordination during Acute Dopamine-Dependent Motor Dysfunction , 2006, Neuron.

[1123]  W. Danysz,et al.  Proteomic analysis of striatal proteins in the rat model of l‐DOPA‐induced dyskinesia , 2007, Journal of neurochemistry.

[1124]  T. Chase,et al.  Milacemide therapy for Parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[1125]  S. Dunnett,et al.  Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. , 2010, Progress in brain research.

[1126]  A. Rajput,et al.  Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial , 1997, Neurology.

[1127]  V. Gurevich,et al.  Dopamine Receptors and the Treatment of Parkinson's Disease , 2010 .

[1128]  M. Barrot,et al.  DeltaFosB: a sustained molecular switch for addiction. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[1129]  R. Moratalla,et al.  Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA–Induced Dyskinesia and Histone Activation , 2009, Biological Psychiatry.

[1130]  P. Blanchet,et al.  Molecular basis of levodopa-induced dyskinesias. , 2000, Annals of neurology.

[1131]  Qin Li,et al.  Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia , 2010, PloS one.

[1132]  S. Dunnett,et al.  Comparison of rating scales used to evaluate l-DOPA-induced dyskinesia in the 6-OHDA lesioned rat , 2013, Neurobiology of Disease.

[1133]  Ulf Bömer,et al.  High‐Throughput Screening for Kinase Inhibitors , 2005, Chembiochem : a European journal of chemical biology.

[1134]  D. James Surmeier,et al.  Re-emergence of striatal cholinergic interneurons in movement disorders , 2007, Trends in Neurosciences.

[1135]  P. Greengard,et al.  Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in l-DOPA treatment of an animal model of Parkinsonism , 2008, Proceedings of the National Academy of Sciences.

[1136]  E. Roubos,et al.  The gray area between synapse structure and function—Gray's synapse types I and II revisited , 2011, Synapse.

[1137]  E. Bézard,et al.  Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease , 2004, Journal of Pharmacology and Experimental Therapeutics.

[1138]  A. Lees,et al.  Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[1139]  A. Schapira,et al.  Test for LRRK2 mutations in patients with Parkinson’s disease , 2008, Practical Neurology.

[1140]  Paul Greengard,et al.  Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in l-DOPA-Induced Dyskinesia , 2007, The Journal of Neuroscience.

[1141]  L Teare,et al.  Cannabis for dyskinesia in Parkinson disease , 2004, Neurology.

[1142]  D. Balfour,et al.  Nicotine: from molecular mechanisms to behaviour. , 2005, Current opinion in pharmacology.

[1143]  S. Wonnacott,et al.  alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. , 2000, Molecular pharmacology.

[1144]  T. Matsuda,et al.  Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats. , 2012, European journal of pharmacology.

[1145]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.

[1146]  G. Arbuthnott,et al.  Plasticity of Synapses in the Rat Neostriatum after Unilateral Lesion of the Nigrostriatal Dopaminergic Pathway , 1998, The Journal of Neuroscience.

[1147]  E. Bézard,et al.  Dopamine receptors and L-dopa-induced dyskinesia. , 2009, Parkinsonism & related disorders.

[1148]  R. Djaldetti,et al.  Riluzole for le vodopa-induced dyskinesias in advanced P arkinson's disease , 1999, The Lancet.

[1149]  P. Calabresi,et al.  A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia , 2006, The Journal of Neuroscience.

[1150]  M. Hornberger,et al.  Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study , 2013, Neurology.

[1151]  S. Shapiro ALLOPURINOL AND BONE-MARROW DEPRESSION , 1974 .

[1152]  C. Olanow,et al.  Modeling Parkinson's disease , 2009, Annals of neurology.

[1153]  R. Eglen,et al.  Drug discovery and the human kinome: recent trends. , 2011, Pharmacology & therapeutics.

[1154]  P. Calabresi,et al.  Permissive role of interneurons in corticostriatal synaptic plasticity , 1999, Brain Research Reviews.

[1155]  K. Saitoh,et al.  Basal ganglia efferents to the brainstem centers controlling postural muscle tone and locomotion: a new concept for understanding motor disorders in basal ganglia dysfunction , 2003, Neuroscience.

[1156]  A. Benabid,et al.  Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease , 1997, The Lancet.

[1157]  D. Erlij,et al.  6-OHDA-induced hemiparkinsonism and chronic l-DOPA treatment increase dopamine D1-stimulated [3H]-GABA release and [3H]-cAMP production in substantia nigra pars reticulata of the rat , 2008, Neuropharmacology.

[1158]  T. Deak,et al.  Contribution of the striatum to the effects of 5‐HT1A receptor stimulation in L‐DOPA‐treated hemiparkinsonian rats , 2009, Journal of neuroscience research.